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Emily R. Mason 
EPILEPSY MUTATIONS IN DIFFERENT REGIONS OF THE NAV1.2 CHANNEL CAUSE 
DISTINCT BIOPHYSICAL EFFECTS 
While most cases of epilepsy respond well to common antiepileptic drugs, many 
genetically-driven epilepsies are refractory to conventional antiepileptic drugs.  Over 
250 mutations in the Nav1.2 gene (SCN2A) have been implicated in otherwise idiopathic 
cases of epilepsy, many of which are refractory to traditional antiepileptic drugs.  Few of 
these mutations have been studied in vitro to determine their biophysical effects on the 
channels, which could reveal why the effects of some are refractory to traditional 
antiepileptic drugs.  The goal of this dissertation was to characterize multiple epilepsy 
mutations in the SCN2A gene, which I hypothesized would have distinct biophysical 
effects on the channel’s function.  I used patch-clamp electrophysiology to determine 
the biophysical effects of three SCN2A epilepsy mutations (R1882Q, R853Q, and L835F).  
Wild-type (WT) or mutant human SCN2A cDNAs were expressed in human embryonic 
kidney (HEK) cells and subjected to a panel of electrophysiological assays.  I predicted 
that the net effect of each of these mutations was enhancement of channel function; 
my results regarding the L835F and R1882Q mutations supported this hypothesis.  Both 
mutations enhance persistent current, and R1882Q also impairs fast inactivation.  
However, examination of the same parameters for the R853Q mutation suggested a 
decrease of channel function.  I hypothesized that the R853Q mutation creates a gating 
pore in the channel structure through which sodium leaks into the cell when the 
channel is in its resting conformation.  This hypothesis was supported by 
viii 
electrophysiological data from Xenopus oocytes, which showed a significant voltage-
dependent leak current at negative potentials when they expressed the R853Q mutant 
channels.  This was absent in oocytes expressing WT channels.  Overall, these results 
suggest that individual mutations in the SCN2A gene generate epilepsy via distinct 
biophysical effects that may require novel and/or tailored pharmacotherapies for 
effective management. 
 
Theodore Cummins, Ph.D., Chair 
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I.  INTRODUCTION 
Overview 
Epilepsy is a set of devastating neurological disorders of the brain that cause 
seizures.  The majority of epilepsy patients find that their seizures are effectively 
repressed by one or a combination of conventional antiepileptic drugs (AEDs).  
However, around 38% of epilepsy patients are refractory to these drugs and have great 
difficulty managing and repressing their seizures (French et al., 2007; Beleza et al., 2009; 
Loescher et al., 2013; Laxer et al., 2014; Moshe et al., 2015; Sirven et al., 2016).  For 
such patients, when the root cause of their epilepsy is unknown despite imaging studies 
and neurological workups, genetic testing is often performed.  There are many genes 
that are believed to be involved in the pathogenesis of epilepsy when they are mutated, 
including voltage-gated sodium channel (Nav) genes.  One of the particular Nav genes 
that is often revealed to be mutated in cases of otherwise idiopathic epilepsy is Nav1.2, 
which is expressed in the membranes of neurons in the brain and is responsible, along 
with Nav1.6, for the generation and propagation of action potentials in excitatory 
neurons.  Epilepsy is a result of an imbalance of excitatory and inhibitory neuron firing in 
the brain, so Nav1.2 mutations implicated in epilepsy pathogenesis are believed to 
enhance the activity of affected channels, leading the affected neurons to be 
hyperexcitable.  This hyperexcitability causes the affected neurons to fire action 
potentials inappropriately, and the inappropriate neuronal activity is believed to play a 
key role in the generation of epileptic seizures.   
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As expected, many Nav1.2 mutations implicated in epilepsy have been shown, so 
far, to have effects on the channel that enhance the channel function.  However, sodium 
channel blockers do not effectively suppress seizures in many of these patients, or in a 
majority of other patients with putatively epileptic Nav1.2 mutations.  While some 
patients have found one or more sodium channel blockers to be helpful in reducing the 
severity or frequency of their seizures, few achieve seizure freedom with any 
antiepileptic drug (AED) or drug combination.  In order to find pharmacotherapies that 
more effectively repress seizures in epileptic patients with Nav1.2 mutations, we must 
develop a better understanding of how the mutations are affecting the activity of the 
channels and why sodium channel blockers have limited efficacy for these patients.  The 
primary aim of this study was to uncover the effects of three mutations on the 
biophysical activity of the Nav1.2 channel in order to identify aberrant channel functions 
that may represent novel AED targets. 
Voltage-Gated Sodium (Nav) Channel Overview 
The first evidence of voltage-gated sodium channels was discovered by Hodgkin 
and Katz in 1948, when these scientists observed that the sodium in the solution 
surrounding a giant axon from a squid was necessary for the axon to fire an action 
potential (Hodgkin & Katz, 1949).  They and other scientists showed that action 
potentials, aka "nerve impulses," involve sodium flowing into the nerve and potassium 
flowing out (Rothenberg, 1950; Keynes & Lewis, 1951).  Hodgkin and Huxley proposed 
that action potentials resulted from three ionic current components:  sodium current 
(INa), potassium current (IK), and a small leak current (Il) comprised of chloride and other 
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ions (Hodgkin & Huxley, 1952).  They observed that the sodium and potassium currents 
flowed through the membrane with different voltage dependent and kinetic properties, 
so they hypothesized that there were two separate conduction mechanisms, which are 
now known to be voltage-gated sodium and potassium channels, which allowed these 
ions to pass through the membrane (Hodgkin & Huxley, 1952).  For sodium, they 
proposed that there were charged particles in the membrane which shifted when the 
membrane potential depolarized, into a conformation allowing the sodium ions to move 
through the membrane until a slow-moving particle, which is now known as the 
inactivation particle, shifts to block the flow of sodium ions (Hodgkin & Huxley, 1952).  
They proposed a similar mechanism for potassium, in which the charged particles 
shifted more slowly, so that the potassium conductance across the membrane peaked 
subsequently to the sodium conductance. 
  Voltage-gated sodium (Nav) channels were first isolated from animals in the 
early 1970s (Henderson & Wang, 1972; Levinson & Ellroy, 1973).  In the early 1980s, 
saxitoxin, which was known to block sodium currents in nerves, was utilized to capture 
and isolate Nav channels from rat brains (Beneski & Catterall, 1980; Hartshorne & 
Catterall, 1981).  Gel electrophoresis of the isolated proteins showed that the sodium 
channel consisted of one large (alpha) subunit and two smaller (beta) subunits 
(Hartshorne & Catterall, 1981; Hartshorne et al., 1982).  In the mid-1980s, two Nav 
channel isoforms were isolated from rat brain and studied in order to deduce their DNA 
sequence, amino acid sequence, and approximate 2D structure (Noda et al. 1984, 
1986a).  The cDNA for these channels was then generated and injected into Xenopus 
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oocytes and found to produce functional rat brain sodium channels (Noda et al., 1986b), 
establishing the idea that the alpha subunits form fully functional channels without 
requiring any beta subunits.  
Eventually, it was determined that there are 9 isoforms of the mammalian 
voltage-gated sodium channel (Nav) alpha subunit, termed Nav1.1-Nav1.9 and encoded 
by the genes SCN1A-SCN5A and SCN8A-SCN11A (Goldin et al., 2001).  These voltage-
gated sodium (Nav) channels are expressed in the plasma membranes of excitable cells, 
and they all share a common basic structure (shown in Fig. 1A-C), which consists of four 
structurally homologous domains, termed DI-DIV (Noda et al., 1984; Sato et al., 1998).  
Each domain consists of six transmembrane segments, termed S1-S6.  The S4 segments 
are known as voltage-sensing segments, since each contains several positively-charged 
amino acid side chains that react to changes in the membrane potential by shifting and 
causing a conformational change in the channel protein (Noda et al., 1984; Stuehmer et 
al., 1989; indicated in Fig. 1A by shading and “+” symbols).  The S5 and S6 segments of 
the four domains form the central pore, and the extracellular linkers between the S5 
and S6 segments, known as pore loops, dip down slightly into the pore.  A cluster of one 
residue from each of the four pore loops form the selectivity filter, which selectively 
interacts with sodium ions, allowing them, but not most other ions or molecules, to pass 
through into the central pore.  When the membrane is at its resting potential (~-70 mV 
for neurons), the channel is in the closed conformation, in which the central pore is 
blocked and sodium cannot pass through into the cell, down its electrochemical 
gradient (Fig. 1C).  When receptors on the postsynaptic neuron are activated by an 
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excitatory stimulus, the membrane depolarizes, due to either an intracellular buildup of 
cations or the efflux of anions.  In response to the membrane depolarization, the 
voltage-sensing segments of Nav channels shift and cause the channels to enter the 
activated conformation, in which the barrier within the pore is removed and sodium is 
allowed to pass through into the cell.  When the membrane potential is depolarized, the 
inactivation particle, which is an amino acid motif in the linker between domains III and 
IV, interacts with a site in or near the intracellular side of the central pore, occluding the 
channel and cutting off the sodium current in a process known as fast inactivation.  
Subsequently, Nav channels are believed to enter a slow-inactivated state, which is 
independent of the inactivation particle and happens over a matter of seconds.  
However, the mechanism and roles of slow inactivation in the contexts of neuronal 
excitability and disease are poorly understood.  At strongly depolarized membrane 
potentials, voltage-gated potassium channels open, and potassium flows out of the cell, 
down its concentration gradient, repolarizing the membrane potential.  As the resting 
membrane potential is restored, the channel shifts back into its resting (closed) 
conformation and the inactivation particle dissociates from the central pore.  In whole-
cell patch clamp electrophysiology experiments, under voltage clamp (see Sigworth 
1980 for description of methodology), the inward current is represented by a downward 
deflection of the current trace (Fig. 1D).   
  There are four β subunits, termed β1-β4, which associate with the α subunits 
and modify their activity, thus modulating the excitability of the neurons (or other 
excitable cells) in which they are expressed.  These subunits, encoded by the genes 
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Scn1b-Scn4b, each contain an extracellular N-terminal V-type Ig domain, a single α-
helical transmembrane segment, and an intracellular C-terminal domain.  The β2 and β4 
subunits covalently bond to α subunits via disulfide bridges, while β1 and β3 interact 
non-covalently with α subunits (Chen et al., 2012; Buffington & Rasband, 2013).  The β 
subunit isoforms are differentially expressed in different excitable tissues and in 
different neuronal subpopulations.  The effect of a β subunit on the α subunit activity 
depends on the β subunit isoform, the α subunit isoform, and the cell type in which they 
are studied; and these effects can include alterations of the voltage dependencies 
and/or gating kinetics of activation and inactivation.  Additionally, the β subunits have 
been shown to function as cell adhesion molecules, via their Ig domain and 
independently of α subunits, (Srinivasan et al., 1998; Xiao et al., 1999) and to play roles 
in neurite outgrowth (Davis, Chen, & Isom, 2004; Miyazaki et al., 2007).   
The nine isoforms of Nav1 channels differ in tissue distribution.  Nav1.1, Nav1.2, 
Nav1.3, and Nav1.6 are found in the central nervous system, while Nav1.1, Nav1.6, 
Nav1.7, Nav1.8, and Nav1.9 are expressed in the peripheral nervous system.  Nav1.4 
and Nav1.5 are expressed in skeletal muscle and heart tissue, respectively. Therefore 
mutations in different Nav isoforms that alter their functions can result in different 
types of diseases.  For instance, mutations in neuronal isoforms have been implicated in 
autism, epilepsy, schizophrenia, pain, and movement disorders; while mutations in the 
cardiac isoform (Nav1.5) are associated with cardiac diseases such as Brugada 
Syndrome, Long-QT Syndrome, and arrhythmias. 
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Nav Channels of the Brain 
Voltage-gated sodium channels were first observed in mammalian brains, 
through stains of voltage gated sodium channels in rodent brains, in the early 1980's; 
and these have since been identified as the Nav1.1, Nav1.2, and Nav1.6 isoforms 
(Westenbroek, Merrick, & Catterall, 1989; Westenbroek, Noebels, & Catterall, 1992; 
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Gong et al., 1999; Caldwell et al., 2000).  Subsequent studies have confirmed the 
presence of those same three isoforms, along with Nav1.3, in human brain tissue 
(Whitaker et al., 2001; Tian et al., 2014).  The same studies also confirmed that the 
expression patterns of the various isoforms throughout the brain were similar between 
rodents and humans.  While Nav1.6 channels are found in most neurons throughout the 
brain (Whitaker et al., 2001; Tian et al., 2014), Nav1.1 and Nav1.2 are rarely, if ever, co-
expressed.  Nav1.1 is found primarily in GABAergic interneurons (Yu et al., 2006; Tian et 
al., 2014), while Nav1.2 and Nav1.6 are found primarily in excitatory neurons (Tian et al., 
2014).  Subcellularly, Nav1.2 is localized primarily in the dendrites, soma, and proximal 
axon initial segment (AIS); and Nav1.6 is concentrated in the distal AIS (Tian et al., 2014; 
Hu et al., 2009).  Early in development, before neurons are myelinated, Nav1.2 can be 
found clustered along the axon at sites that later become nodes of Ranvier; but these 
clusters are replaced with Nav1.6 clusters once the axons are myelinated (Kaplan et al., 
2001).  Nav1.3 is also strongly expressed in some regions of the fetal brain, but by 
adulthood its expression is weak and predominantly somatodendritic (Whitaker et al., 
2001; Smith et al., 2018).  Nav1.1 expression is low during the prenatal period and 
increases postnatally, showing a similar subcellular localization to Nav1.3 (Whitaker et 
al., 2001; Smith et al., 2018).  Given the preferential expression of Nav1.6 in the distal 
AIS and nodes of Ranvier of neurons, Nav1.6 is generally regarded to be the 
predominant isoform responsible for action potential initiation and propagation (Hu et 
al., 2009).  Nav1.1, Nav1.2, and Nav1.3 have a stronger presence in the dendrites, soma, 
and proximal AIS, and they are thus believed to be responsible for action potential 
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backpropagation (Westenbroek, Merrick, anc Catterall, 1989; Trimmer and Rhodes, 
2004).  Nav1.2 is often found in the AIS and is thus is believed to be involved in action 
potential initiation (Rush, Dib-Hajj, and Waxmann, 2005; Kaczmarek, 2019).  
Backpropagation of action potentials into the soma and dendrites of neurons is poorly 
understood, but it is believed to play a role in synaptic plasticity and synchrony 
(Kuczewski, Porcher, and Ferrand, 2008; Kuczewski et al., 2008; Spratt et al., 2019; Shin 
et al., 2019). 
Epilepsy 
Epilepsy is a devastating set of disorders caused by aberrant bursts of 
synchronous neuronal activity in the brain.  Epilepsy was first associated with voltage-
gated sodium (Nav) channels in 1998, when two mutations in the Nav β1 subunit gene, 
Scn1b, were identified as likely pathogenic mutations in two families in which 
generalized epilepsy with febrile seizures (GEFS+) was known to have been genetically 
transmitted (Wallace et al., 1998).  Since then, mutations in each of the brain voltage 
gated sodium channel isoforms (Nav1.1, Nav1.2, Nav1.3, and Nav1.6) have been 
identified in otherwise idiopathic cases of epilepsy (see Noebels, 2019 for review).  
Some of these epilepsy mutations are passed down in families, but many are de novo 
mutations not present in either parent.   
While most epilepsy cases respond well to common antiepileptic drugs, about 
38% of epilepsy patients experience persistent seizures under conventional epilepsy 
treatments (French et al., 2007; Beleza et al., 2009; Loescher et al., 2013; Laxer et al., 
2014; Moshe et al., 2015; Sirven et al., 2016). Most of these refractory epilepsies are 
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believed to be manifestations of a genetic defect (Mercimek-Mahmutoglu et al., 2015).  
Mutations in 18 genes, including genes encoding voltage-gated sodium channels (Nav 
channels) expressed in the brain (SCN1A, SCN1B, SCN2A, and SCN8A, encoding Nav1.1 α 
and β subunits, Nav1.2 α subunit, and Nav1.6 α subunit), have been identified in several 
types of epilepsy (Nicita et al., 2012).  Since Nav1.2 and Nav1.6 are predominantly 
expressed in excitatory neurons, it is believed that epileptic mutations in these channel 
isoforms typically cause the channels to conduct too much sodium current into the 
affected neurons, resulting in neuronal hyperexcitability.  The hyperexcitability leads to 
the inappropriate bursts of action potential firing characteristically seen in epileptic 
seizures.  Mutations that enhance Nav channel function or induce an aberrant function 
in the channel are generally (and hereafter) referred to as gain-of-function effects.  
Alternately, since Nav1.1 is primarily expressed in inhibitory interneurons, which act to 
decrease excitation in their postsynaptic excitatory neurons, epileptic mutations in this 
isoform usually cause a decrease in the conductance of the sodium current into the 
interneurons; these are generally (and hereafter) referred to as loss-of-function effects.  
Affected interneurons are not as excitable as healthy (WT) neurons and do not fire 
action potentials as often as they should, and thus the postsynaptic excitatory neurons 
are disinhibited and can become hyperexcitable.   
The opening of Nav1.2 and Nav1.6 channels in the AIS allows entry of sodium 
into neurons and is responsible for the initiation and propagation of action potentials 
down the axons (Catterall et al., 2005).  If these voltage-gated sodium channels allow 
too much sodium to enter the cell, the resting membrane potential may be elevated, 
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thus reducing the action potential firing threshold.  This means that small depolarizing 
postsynaptic potential changes, which would not bring the potential past the threshold 
voltage in a healthy cell, may bring the potential past the threshold value and cause 
action potentials to be fired.  This would enhance repetitive firing (e.g. increased 
frequency and duration of action potential firing) in these neurons in response to 
depolarizing currents, leading to an abnormally large and/or sustained neurotransmitter 
release (Wang et al., 2016).  In epilepsy, the chronically elevated resting membrane 
potentials of excitatory (glutamatergic) neurons leads to aberrant glutamate release, 
which excites downstream neurons and results in the seizure phenotype (During et al., 
1993; Broomfield et al., 2006). 
Nav1.2 and Molecular Mechanisms of Epilepsy 
Mutations in SCN2A , the gene encoding the pore-forming α subunit of the 
Nav1.2 channel, can lead to multiple types of epilepsy including Dravet Syndrome, 
genetic epilepsy with febrile seizures plus (GEFS+), benign familial neonatal-infantile 
seizures (BFNIS), early onset epileptic encephalopathies (EOEE), and Ohtahara Syndrome 
(Brunklaus et al., 2014; Shi et al., 2012).  These mutations can modify different 
parameters of channel function, including the voltage-dependence of gating (e.g. the 
voltage dependence of activation and inactivation), the kinetics of gating (e.g. the time 
constant for fast inactivation), and/or the transient current (INaT) magnitude (e.g. INaT 
peak amplitude, INaT peak density).  Additionally, some of these epileptic SCN2A 
mutations induce or alter existing aberrant inward sodium currents, such as persistent, 
resurgent, and gating pore currents (Rogawski et al., 2004; Jarecki et al., 2010; Hargus et 
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al., 2011; Hargus et al., 2013; Lewis and Raman, 2014).  Since the Nav1.2 channel 
isoform is primarily expressed in glutamatergic neurons, epilepsy mutations in this 
protein are believed to cause a net augmentation of the channel function, leading to 
hyperexcitability and inappropriate action potential firing.   
Mutations in SCN2A that confer a loss of channel function, which typically leads 
to reduced neuronal excitability, have also been implicated in autism.  Most of the 
SCN2A mutations that have been reported which result in premature truncation of the 
protein have been associated with autism.  All such mutations that have been studied in 
vitro have been shown to produce non-conducting channel fragments (Kamiya et al., 
2004; Ben-Shalom et al., 2017).  Two of these mutations have been shown to diminish 
the function of WT channels when mutant and WT channels were coexpressed; and 
most or all other SCN2A mutations that have been found to have exclusively loss-of-
function effects are associated with a clinical diagnosis of autism (Kamiya et al., 2004; de 
Rubies et al., 2014; Ben-Shalom et al., 2017; Wolff et al., 2017).  Among SCN2A 
mutations associated with epilepsy or seizures, autism diagnoses were reported in all 
cases associated with mutations that have been shown to produce exclusively loss-of-
function effects, and only in one case of a mutation with a mix of gain-of-function and 
loss-of-function effects (Scalmani et al., 2006; Misra et al., 2008; Wolff et al., 2017).  
Functional modeling of the impact of SCN2A mutations on neuronal excitability 
predicted that several mutations implicated in autism decrease neuronal excitability, 
while several associated with epilepsy increase neuronal excitability (Ben-Shalom et al., 
2017).  This suggests that SCN2A mutations that result in a loss of channel function 
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typically lead to decreased neuronal excitability and autism (which is sometimes 
accompanied by seizures), while mutations that enhance the channel function (i.e. have 
gain-of-function effects) or have mixed effects on channel function tend to cause 
neuronal hyperexcitability and epilepsy (which is rarely associated with a diagnosis of 
autism).   
Over 250 mutations in the SCN2A gene have been implicated in published cases 
of epilepsy (Fig. 2A), but only 21 (~8.5%) have been studied and characterized in vitro 
(see Table 1).  Of these 21 mutations, 10 have been reported to cause only gain-of-
function effects, including increased current density, hyperpolarized voltage 
dependence of activation, depolarized voltage dependence of fast inactivation, slowed 
fast inactivation, accelerated recovery from inactivation, increased persistent currents, 
and increased resurgent currents.  Persistent current, also called late current, is the 
current that occurs after most of the Nav channels have opened and inactivated.  This is 
due to either incomplete inactivation or brief dissociations of the inactivation particle 
from the central pore (Fig. 3A).  Resurgent currents occur when there is an intracellular 
blocking molecule present, which binds to the central pore upon depolarization, 
blocking the transient current and hindering the interaction of the inactivation particle 
with the central pore.  Upon repolarization, the blocking molecule dissociates and 
current briefly resurges through the central pore before it is again cut off by the 
inactivation particle (Fig. 3B-C). 
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Persistent and resurgent current have both been shown to naturally occur in 
mammalian neurons.  Persistent currents have been observed in many populations of 
neurons in mammalian brains, including subicular neurons from patients with temporal 
lobe epilepsy (Vreugdenhil et al., 2004).  Persistent currents have been shown to occur 
in the soma and proximal processes of healthy adult rat CA1 pyramidal cells (Yue et al., 
2005); which have been shown to strongly express Nav1.2 (Gong et al., 1999).  
Resurgent current has been shown to occur in brain regions that have been reported to 
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express Nav1.2, including the globus pallidus (Gong et al., 1999 (Nav1.2); Yu et al., 2003; 
Mercer et al., 2007 (INaR)), dentate gyrus (Whitaker et al., 2001 (Nav1.2); Yu et al., 
2003; Castelli, Biella, et al., 2007 (INaR)), and hippocampal CA1 pyramidal neurons 
(Whitaker et al., 2001; Liao, Deprez, et al., 2010 (Nav1.2); Yu et al., 2003; Castelli, Biella, 
et al., 2007; Buffington & Rasband, 2013 (INaR)).   Though no study has definitively 
shown that human neurons expressing Nav1.2 also express resurgent current, 
recordings from mouse DRG neurons have demonstrated that Nav1.2 channels can 
produce resurgent currents in a neuronal background (Rush et al., 2005).  Since 
resurgent current requires a blocking molecule, there must be at least one blocking 
molecule endogenously expressed in these neuronal populations.  So far, only two such 
proteins endogenous to neurons have been identified as responsible for generating 
resurgent currents:  Navβ4 and FGF14b.  It has been shown that Navβ4 and FGF14b, 
which are both endogenous to mouse cerebellar Purkinje neurons, are responsible for 
generating the endogenous resurgent current seen in these neurons (Wang et al., 2002; 
Grieco et al., 2005; Bant & Raman, 2010; Yan et al., 2014; White et al., 2019).  A peptide 
from the intracellular portion of the Navβ4 protein (KKLITFILKKTREK-OH), referred to as 
the Navβ4 peptide, has been shown to induce resurgent current in multiple cell types 
expressing Nav channels (Aman et al., 2009; Grieco et al., 2005; Wang et al., 2006; Kim 
et al., 2010; Lewis and Raman, 2011; Thiele et al., 2011 , Patel et al., 2015).  There may 
also be additional endogenous molecules in neurons that act as blocking molecules to 
induce resurgent currents.   
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Enhancement of persistent, resurgent, and gating pore currents are believed to 
cause hyperexcitability in affected neurons.  Persistent currents have been shown to 
support burst firing in neurons from mammalian brains (Yue et al., 2005; Van Drongelen 
et al., 2006).  Resurgent currents have been identified as drivers of both repetitive 
action potential activity and spontaneous action potential generation (Raman and Bean, 
1997; Bant and Raman, 2010; Khaliq et al., 2003; Barbosa et al., 2015; Xiao et al., 2019).  
Increases in both persistent and resurgent currents through Nav channels have been 
correlated with increased action potential frequency and burst firing (Raman & Bean, 
1997; Khaliq et al., 2003; Afshari et al., 2004; Yue et al., 2005; Van Drongelen et al., 
2006; Kim et al., 2010; Hargus et al., 2013; Barker et al., 2017).   
Persistent currents have been shown to be increased in rat hippocampal neurons 
from multiple epilepsy models (Royeck 2015 & others); and large persistent currents 
have been observed in subicular (hippocampal) neurons from human epileptic patients 
(Vreugdenhil et al. 2004).  Several SCN2A epilepsy mutations (Liao et al., 2010 (M252V, 
V261M); Lauxmann et al., 2013; Schwarz et al., 2016; Parrini et al., 2017 (A263V); Wolff 
et al., 2017) have also been shown to increase persistent currents through Nav1.2. 
Resurgent currents are also enhanced by pro-excitatory disease mutations in other 
voltage-gated sodium channel isoforms which are associated with pain, myotonia 
congenital, long-QT syndrome, and SCN8A epilepsies (Jarecki et al., 2010; Patel et al., 
2016; Xiao et al., 2019).  Ours is the first study to investigate the impact of SCN2A 
disease mutations on resurgent currents. 
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 Augmentation of persistent currents is often accompanied by augmentation of 
resurgent currents (Thiele et al., 2011; Barker et al., 2017).  This concurrent 
augmentation has been seen in hippocampal neurons after induction of epilepsy in 
three rodent models (Hargus et al., 2013; Barker et al., 2017; Ottolini et al., 2017; Shao 
et al., 2017) and is associated with neuronal hyperexcitability and repetitive firing 
(Barker et al., 2017; Hargus et al., 2013; Van Drongelen et al., 2006; Yue et al., 2005; Kim 
et al., 2010; Raman and Bean, 1997; Khaliq et al., 2003; Afshari et al., 2004).   
 Six of the 21 SCN2A mutations characterized so far are reported to have only 
loss-of-function effects, and five have been shown to have a combination of gain- and 
loss-of-function effects.  Loss-of-function effects, which diminish the channel function, 
include faster inactivation, depolarized voltage dependence of activation, 
hyperpolarized voltage dependence of inactivation, slowed recovery from inactivation, 
and decreased persistent currents; and they are believed to decrease neuronal 
excitability by decreasing the buildup of sodium ions in affected neurons.   Since Nav1.2 
is believed to be primarily expressed in glutamatergic neurons, the idea that some 
epilepsy mutations in this channel isoform decrease [glutamatergic] neuronal 
excitability challenges the dogma that the pathogenic effects of all epilepsy mutations in 
this isoform must enhance neuronal excitability by enhancing or augmenting the 
intracellular accumulation of sodium ions.  Thus, any time loss-of-function effects are 
found to result from Nav1.2 epilepsy mutations, they complicate the interpretation of 
the overall mutation effects.  When loss-of-function effects are revealed alongside gain-
of-function effects, it can often be reasonably argued that the gain-of-function effects 
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likely prevail over the loss-of-function effects, resulting in a net gain of function and 
enhancement of neuronal excitability.  Other possible interpretations of a mutation with 
mixed effects include that it is not responsible for the epilepsy, that some other protein 
or molecule that is not accounted for in the experimental studies modifies the channel 
activity to produce a net enhancement of channel function, or that there is another 
functional effect of the mutation that has not been considered.  One such effect that a 
Nav disease mutation may have on the channel is the induction of a gating pore current.  
It has been shown that the mutation of voltage-sensing residues in multiple Nav 
channels, including Nav1.4 and Nav1.5 disease mutations, induces a cationic inward leak 
current that is absent in wild-type channels (Sokolov et al. 2005, 2007, 2008, 2010; 
Struyk et al., 2007; Wu et al., 2011; Gosselin-Badaroudine et al., 2012; Gamal El-Din et 
al., 2014; Xiao, Blumenthal, and Cummins, 2014; Moreau et al., 2015; Jiang et al., 2018).  
Molecular dynamic simulations of these mutations support the idea that they create an 
anomalous pore, separate from the central pore, that supports cationic current (Fig. 4; 
Gosselin-Badaroudine et al., 2014; Jiang et al., 2018).  Since the gating pore is 
structurally distinct from the central pore, gating pore currents are unimpeded by 
tetrodotoxin (TTX), which binds within the central pore and inhibits transient currents.  
These gating pore currents have primarily been observed in Xenopus oocytes expressing 
the channels of interest, though they have also been observed in HEK cells expressing 
Nav1.5 (Xiao, Blumenthal, and Cummins, 2014).  Only one study has demonstrated that 
mutations of voltage-sensing arginine residues in Nav1.2 can generate gating pore 
currents (Sokolov et al, 2005). A study of the bacterial Nav channel, NaChBac, suggested 
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that neutralization mutations of the first or second arginine residues (from the 
extracellular side of the membrane) in the voltage sensing segment can result in a gating 
pore that is open when the channel is in the resting state and closed when the channel 
is open or inactivated.  Alternatively, it suggested that a neutralizing mutation of the 
third arginine residue can result in a gating pore that opens when the channel is open or 
inactivated and closed when the channel is in the resting state (Gamal El-Din et al., 
2014).  This phenomenon was confirmed, for the two outermost arginine residues, in rat 
Nav1.2 (Sokolov et al., 2005), though no resurgent current was observed when the third 
arginine residue was mutated.   
 Aberrant trafficking and cell surface expression of Nav channels is also believed 
to contribute to neuronal hyperexcitability (Mantegazza et al., 2010; Rusconi et al., 
2007).  This is evidenced by the reduced surface expression of BFNIS Nav1.2 mutants 
R1319Q, L1330F, and L1563V (loss-of-function mutations) as compared to wild-type 
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Nav1.2 channels (Misra et al., 2008) and the increased expression of these channels in 
granule cells with the gain-of-function mutation A263V (Liao, Anttonen, et al., 2010).  
Rat models of temporal lobe epilepsy also demonstrate changes in Nav channel 
expression and localization that are associated with changes in neuronal excitability and 
Nav channel function.  Hippocampal neurons from rat models of temporal lobe epilepsy 
have reduced mRNA expression of Nav1.2 & Nav1.3 (Aronica et al., 2001) and altered 
Nav gating properties (Ketelaars et al., 2001) after induction of status epilepticus in the 
rats.  The mEC layer II neurons from these rats also showed increased action potential 
firing, increased persistent and resurgent Nav currents, increased staining of Nav1.6 at 
the axon initial segment, and increased staining of Nav1.2 in the cell bodies, compared 
to the same population of neurons from age-matched control animals (Hargus et al., 
2011).  These findings suggest that changes in Nav1.2 localization and trafficking to the 
plasma membrane may contribute to the pathophysiology of some forms of epilepsy.   
Antiepileptic Drug Strategies 
 Since epilepsy is characterized by inappropriate excitatory signaling in the 
brain, the overarching goal of antiepileptic therapies is to restore the proper balance of 
excitatory and inhibitory signaling in the brain.  There are two primary strategies that 
are employed to achieve this aim:  inhibiting excitatory neuron signaling and enhancing 
inhibitory neuron signaling.  There are over 30 FDA-approved antiepileptic drugs, most 
of which have mechanisms of action that fall under one of those two umbrella 
strategies.  Some drugs act only to inhibit excitatory signaling (including the inhibition of 
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neurotransmitter release), some act only to enhance inhibitory signaling, and some 
employ both strategies. 
 Since Nav1.2 is predominantly expressed in excitatory neurons, and since 
mutations in this protein are generally believed to cause epilepsy through gains of 
channel function, patients whose epilepsy is reasonably attributable to a SCN2A 
(Nav1.2) mutation are generally expected to respond well to sodium channel blockers, 
which act to inhibit excitatory signaling.  Carbamazepine, lacosamide, oxcarbazepine, 
eslicarbazepine acetate, phenytoin, lamotrigine, and rufinamide all inhibit Nav channels 
as their primary mechanism of action, though not necessarily their only mechanism of 
action.  These drugs have all been shown to be state- and frequency-dependent 
blockers, meaning that they bind preferentially to the inactivated conformation of the 
channels and that they have a high potency for hyperactive channels.  Thus, they bind to 
inactivated channels and slow their recovery from inactivation, reducing the overall 
channel availability for the generation of subsequent action potentials.  This reduces the 
occurrence of high-frequency or burst firing that is associated with epilepsy, without 
impeding normal neuronal firing.  Valproate, felbamate, topiramate, and zonisamide are 
antiepileptic drugs that have been shown to block Nav channels; though they are all at 
least suspected to also block calcium channels, and the former three (valproate, 
felbamate, and topiramate) have also been shown to enhance inhibitory (GABA) 
signaling. 
 Carbamazepine, phenytoin, valproate, and topiramate are some of the most 
frequently prescribed drugs for patients with SCN2A-associated epilepsy.  Phenytoin has 
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been reported to have achieved seizure freedom for seven patients with SCN2A 
epilepsy, including two with Ohtahara Syndrome.  However, thirteen other SCN2A 
epilepsy patients found it unhelpful, and it even exacerbated the seizure phenotype in 
one patient.  Other sodium channel blockers that have been reported to grant seizure 
freedom to SCN2A epilepsy patients as monotherapies include carbamazepine, 
valproate, and topiramate.  Five SCN2A epilepsy patients have been reported to have 
achieved seizure freedom with a combination of two drugs, at least one of which is a 
sodium channel blocker; and two more patients have had the same result with a 
combination of three antiepileptic drugs, at least one of which is a sodium channel 
blocker.  Yet, despite the efficacy of these sodium channel blockers in some SCN2A 
epilepsy patients, they prove insufficient to block seizures in others.  Furthermore, these 
AEDs, which some patients may need to take for life, are associated with adverse 
neurological effects such as fatigue, dizziness, and memory problems.  These and other 
adverse effects of the AEDs sometimes severely decrease the patients’ qualities of life; 
therefore, there is a need for new AEDs that can block the mechanism of 
epileptogenesis without producing devastating adverse effects.   
 One of the newest antiepileptics, Brivaracetam, is available as a drug called 
Briviact (UCB, Inc.), which has been approved by the FDA as an antiepileptic for patients 
with partial-onset seizures (Drugs.com, 2020).  Brivaracetam’s primary mechanism of 
action seems to be similar to that of Levetiracetam, which targets a protein called SV2A 
in the membranes of presynaptic vesicles and blocks neurotransmitter release.  
Levetiracetam has also been shown to be a state- and voltage-dependent sodium 
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channel blocker (Zona et al., 2010).  Though another study found brivaracetam to be 
only weakly effective in blocking voltage-gated sodium channel currents in rat 
neocortical neurons and human neuroblastoma cells and completely ineffective in adult 
mouse CA1 neurons (Niespodziany et al., 2015), the drug exhibited good tolerability and 
efficacy in clinical trials comprised of patients with refractory epilepsy (see Feyissa 2019 
for review).  Thus, it is unclear whether or not Brivaracetam’s antagonism of Nav 
channels is involved as a secondary mechanism of its antiepileptic action. 
 An ideal pharmacotherapeutic strategy for any epileptic patient with a 
pathogenic SCN2A mutation may involve selectively targeting the specific pathological 
biophysical effects of each mutation, which often include the enhancement of aberrant 
currents such as persistent and resurgent currents.  Such a strategy would maintain or 
restore healthy channel conductance and gating, as is seen in wild-type hNav1.2 
channels, so as to prevent aberrant action potential firing without producing sedation or 
other adverse effects in patients.  Though there are a few drugs in development that are 
selective for Nav1.7 and/or Nav1.8 over other Nav isoforms, there are no sodium 
channel blockers that are selective for the Nav1.2 isoform, as of 2020.  Furthermore, 
studies suggest that most conventional sodium channel blockers do not preferentially 
block persistent or resurgent currents, which would be a helpful strategy for epileptic 
patients with Nav1.2 mutations that enhance persistent and resurgent currents but do 
not significantly affect the transient current amplitude. 
 Cannabidiol (CBD), a compound found in marijuana, has been demonstrated to 
preferentially inhibit resurgent current over transient current in hNav1.6 channels 
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expressed in HEK cells, while also blocking the enhancement of persistent current by an 
epileptogenic hNav1.6 mutation (Patel et al., 2016).  Though the primary mechanism of 
antiepileptic action of CBD is unclear, it is known to antagonize voltage-gated sodium, 
potassium, and calcium channels; and it has shown promise as an antiepileptic 
compound in both preclinical and clinical studies (Hill et al., 2014; Mao et al., 2015; 
Jones et al., 2010; Patel et al., 2016; Ghovanloo et al., 2018; Devinsky et al., 2016, 2017).  
Additionally, clinical trials have shown that CBD, alone or as an add-on treatment, 
reduces seizure frequency in many patients with refractory epilepsy (Press, Knupp, and 
Chapman, 2015; Devinsky et al., 2016, 2017, 2018; Thiele et al., 2018; Szaflarski et al., 
2018a, 2018b; Savage et al., 2019), which explains why many refractory epilepsy 
patients find relief from seizures with the use of medical marijuana, which contains CBD.  
In June of 2018, a CBD formulation called Epidiolex (a schedule V drug produced by GW 
Pharmaceuticals) became the first form of CBD to gain FDA approval, for the treatment 
of refractory Dravet Syndrome and Lennox-Gestaut Syndrome (Drugs.com, 2019; U.S. 
Food and Drug Administration, 2018).   
 One antiepileptic drug that is making its debut in 2020, cenobamate 
(YKP3089), has been shown to enhance Nav channel inactivation, preferentially block 
persistent sodium current (INaP) over transient sodium current (INaT), and reduce 
excitability in acutely dissociated rat CA3 neurons (Nakamura 2019).  However, it has 
also been shown to be a non-benzodiazepine positive allosteric modulator of GABAA 
receptors, as evidenced by its enhancement of GABAA-mediated currents in rat CA1 
neurons (Sharma et al., 2018).  This compound has been shown to be anticonvulsive in 
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several rodent models of epilepsy as well as in phase 2 trials in human epilepsy patients 
(Bialer et al., 2013, Kasteleijn-Nolst Trenite et al., 2019; Krauss, et al., 2020).  Though 
there are no completed phase 3 studies of cenobamate, it gained FDA approval in 
November of 2019 for the treatment of partial-onset seizures in adults, under the 
commercial name Xcopri (SK Biopharmaceuticals).   
 Another sodium channel blocking compound that has demonstrated 
preferential inhibition of INaP over INaT is GS967/Prax330 (Baker et al., 2018; Wengert 
et al., 2019).  This compound was initially studied as an antiarrhythmic that was found 
to block persistent current over transient current in the cardiac sodium channel, Nav1.5, 
but it is now being repurposed as an antiepileptic compound due to its brain 
permeability and non-selectivity among Nav channel isoforms (Anderson et al., 2014; 
Koltun et al., 2016).  It has been shown to be antiepileptic in a mouse model of Dravet 
Syndrome, which is a type of epilepsy caused by a loss of Nav1.1 function, in the Q54 
mouse genetic model of SCN2A (Nav1.2) epilepsy, and in mice exhibiting epilepsy due to 
the Nav1.6 epilepsy mutations N1768D and R1872W (Anderson et al., 2014, 2017; Baker 
et al., 2018; Bunton-Stasyshyn et al., 2019).  Given this efficacy shown in mouse models 
of genetic epilepsy, GS967/Prax330 will likely continue to be studied as an antiepileptic, 
especially if it continues to show preferential inhibition of persistent over transient Nav 
current.  A phase 1 trial to assess the safety of Prax330 has been completed in Australia, 
but the results have not been publicly reported. 
 Since gating pore current is a novel concept in the pathogenesis of Nav 
channelopathies, there are no published studies on the abilities of current AEDs or other 
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small molecules to block this aberrant current.  There are no molecules known to bind 
Nav channels at the gating pore, so gating pore currents are unlikely to be targeted by 
standard clinical therapies.  Thus, novel approaches may be needed to ameliorate the 
impact of the gating pore currents produced by some neuronal sodium channel disease 
mutations. 
 Though conventional sodium channel blockers are helpful for some epilepsy 
patients, there is still a great need for antiepileptic pharmacotherapies that more 
effectively prevent seizures in patients with SCN2A epilepsy mutations without 
producing disturbing adverse effects.  In vitro studies that examine the biophysical 
effects of epileptic Nav channel mutations and the impacts of various sodium channel 
blocking antiepileptic compounds on the affected channel functions will facilitate the 
tailoring of antiepileptic therapies to the patients based on the specific effects of their 
pathogenic mutation. 
Hypothesis and Experimental Approach 
 In order to better understand how SCN2A mutations cause treatment-resistant 
epilepsy, we must develop an understanding of how these mutations alter the Nav1.2 
channel function.  Since less than 10% of the SCN2A mutations formally reported to be 
implicated in epilepsy have been studied in vitro, this study aimed to characterize three 
more SCN2A mutations in order to expand our understanding of how these mutations 
alter channel function and contribute to treatment-refractory epilepsy.  Thus, the first 
aim of this dissertation was to characterize the effects of three epilepsy mutations on 
human Nav1.2 (hNav1.2) channel function. 
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 We chose to characterize one novel SCN2A/Nav1.2 mutation that has been 
reported in an epileptic patient, L835F, and two that have been repeatedly reported in 
the literature, R853Q and R1882Q.  Because the latter two mutations have been 
reported in many patients whose epilepsy was otherwise idiopathic, I am confident that 
they are implicated in the pathogenesis of the disease in these patients.  The L835F 
mutation has not been identified as a variant in healthy patients, so it is likely to be 
epileptogenic.  The R853Q mutation is one of the most frequently reported 
epileptogenic mutation in Nav1.2 and has been identified in patients diagnosed with 
severe forms of epilepsy including West Syndrome (a.k.a. infantile spasms).  These are 
severe forms of epilepsy that usually have late onsets, are correlated with 
developmental delays and are refractory to multiple antiepileptic drugs.  The R1882Q 
mutation has been identified in one patient diagnosed with Ohtahara Syndrome, as well 
as early-onset epileptic encephalopathies (including early infantile epileptic 
encephalopathy (EIEE) and neonatal onset epileptic encephalopathy (NOEE)).  Most of 
these patients were reported to have severe developmental delays or intellectual 
impairment, but some of them have been able to effectively reduce their seizure 
frequency with high doses of phenytoin.  The patient with the L835F mutation was 
diagnosed with a severe early-onset epilepsy.  Since these mutations affect different 
segments of the hNav1.2 protein, which are involved in different aspects of channel 
function, I hypothesized that these mutations would produce distinct alterations in 
various aspects of hNav1.2 channel function.  The results from the first aim confirmed 
this hypothesis.   
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 It is well known that Nav disease mutations alter various parameters of 
channel gating, including transient and persistent current amplitude/density, as well as 
voltage dependencies and kinetics of activation and inactivation.  While the 
enhancement of persistent and resurgent currents have been shown to underlie 
neuronal hyperexcitability and have both been associated with Nav1.6 epilepsies, 
resurgent currents had not been shown to result from any Nav1.2 disease mutations 
prior to 2019.  Additionally, gating pore currents have been shown to be correlated with 
Nav1.4 disease mutations, but this study is also the first to show that gating pore 
currents can be generated by Nav1.2 mutations and may be implicated in the 
pathogenesis of epilepsy.   
 We chose to study these Nav1.2 mutations by expressing the wild-type or 
mutant channels in HEK cells, which have few or no endogenous Nav channels, in order 
to study the transfected channels in isolation.  I examined most of the same aspects of 
Nav channel function as did previous in vitro electrophysiological studies of other SCN2A 
epilepsy mutations:  transient current magnitude (measured as current amplitude and 
density), voltage dependencies of activation and fast inactivation, kinetics of fast 
inactivation, and persistent current magnitude.  I found that the L835F, R853Q, and 
R1882Q mutation each produce a distinct set of effects on Nav1.2 channel function in 
HEK cells.  I also investigated the effects of the R853Q and R1882Q mutations on the 
amplitude and density of resurgent currents, and found that these two mutations had 
opposite effects on the resurgent current magnitude.  Since point mutations in the DII 
S4 voltage sensor of Nav1.4 have been shown to produce gating pore currents, and 
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given the high degree of conservation of this segment among all Nav isoforms, I 
predicted that the R853Q mutation similarly creates a gating pore current in the Nav1.2 
channel.  Gating pore currents have been clearly demonstrated in Xenopus oocytes but 
are difficult to discern in HEK cells, so I collaborated with the Cannon lab at the 
University of California Los Angeles to demonstrate that the R853Q mutation creates a 
gating pore current that is absent in wild-type channels.  
 Novel antiepileptic compounds are needed in order to more effectively 
prevent seizures in patients with these and many other epileptogenic SCN2A mutations; 
and this could be achieved by developing compounds that specifically target the 
pathogenic effects of the mutations.  Since resurgent current is increasingly being 
implicated in the pathogenesis of Nav-associated epilepsy, I sought to identify 
compounds that preferentially block resurgent or persistent current over transient 
current.  Previous studies indicated that CBD can preferentially block the resurgent over 
transient Nav1.6 current (Patel et al., 2016) and that GS967 can preferentially block 
persistent over transient Nav1.6 current (Baker et al., 2018; Wengert et al., 2019).  Since 
Nav1.6 and Nav1.2 are both predominantly expressed in excitatory neurons in the brain 
and have similar structures and functions, I hypothesized that these compounds would 
express the same preferential current inhibition in HEK cells stably expressing wild-type 
Nav1.2 channels. Thus, the second aim of this dissertation was to test whether CBD and 
GS967 preferentially inhibit resurgent or persistent current in hNav1.2.  The results of 
my preliminary studies support that hypothesis and suggest that, in HEK cells stably 
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expressing WT hNav1.2, CBD preferentially inhibits resurgent current over transient 
current and GS967 preferentially inhibits persistent current over transient current. 
 Overall, this dissertation focuses on the biophysical effects of epileptogenic 
Nav1.2 mutations.  The results of this work expand the scope of pathogenic effects of 
SCN2A mutations to include the enhancement of resurgent currents and the induction 
of gating pore currents.  The results of this research suggest that individual epilepsy 
mutations in a single Nav channel gene produce distinct combinations of biophysical 
effects on the channel function.  Given the large proportion of epilepsy patients whose 
seizures are refractory to conventional antiepileptic drugs, this implies that the patients 
with these mutations may require tailored pharmacotherapies in order to effectively 
suppress their seizures.  The results of this work suggest that targeting specific 
pathogenic biomechanisms of the mutations, such as resurgent and gating pore 
currents, could constitute one novel approach to the identification and development of 
more effective and tailored antiepileptic drugs. 
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II.  MATERIALS AND METHODS 
DNA Constructs 
Codon-optimized human Nav1.2 DNA constructs (wild-type, R1882Q, & R853Q) 
were designed in-house and synthesized by GenScript (Piscataway, NJ).  The amino acid 
sequence for the synthesized wild-type hNav1.2 cDNA construct corresponds with 
NG_008143.1 in the NCBI database.  The SCN2A gene is contained within a pcDNA3.1 
vector and preceded by a CMV promoter.  Synthesized mutant constructs are identical 
to wild-type (WT) aside from the single mutation (R1882Q or R853Q).  Mutagenesis 
(QuickChange II kit, Agilent Technologies, Inc.) was performed on the WT channel 
construct in order to generate the L835F mutant construct.  The entire SCN2A gene 
region of this construct was sequenced (ACGT, Inc.) to ensure that no additional 
mutations were present.  
HEK293 Cell Culture 
The use of HEK293T cells (hereafter referred to as HEK cells; Dubridge et al., 
1987) was approved by the Institutional Biosafety Committee and followed the ethical 
guidelines for the National Institutes of Health for the use of human-derived cell lines. 
HEK cells were grown under standard tissue culture conditions (5% CO2, 37°C) in 
maintenance media consisting of DMEM supplemented with 10% fetal bovine serum 
and 1% penicillin/streptomycin. 
Transient Transfections 
HEK cells were transfected using the calcium phosphate precipitation method.  
Briefly, calcium phosphate-DNA mixture [2 μg channel construct and 1 μg enhanced 
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green fluorescent protein (EGFP)] was added to cells in serum-free media for 8-17 
hours, after which the cells were washed with maintenance media and the serum-free 
media was replaced with maintenance media.  Transfected cells were identified by 
presence of fine particulate coating the cells before washing and by expression of EGFP 
using a fluorescent microscope.  Whole-cell patch clamp recordings were obtained 36-
48h post-transfection. 
Generation of Cell Lines Stably Expressing hNav1.2 
Cell lines stably expressing hNav1.2 channels were generated by transfecting 
cells with the wild-type or mutant channel construct, which contains a gene conferring 
resistance to geneticin (G418).  The calcium phosphate precipitation method of 
transfection was used, including replacement of media 8-17h post-transfection.  48h 
post-transfection, the cells were split into a 100mm dish and G418 (500 μg/mL) was 
added to the media.  Media, including G418, was replaced 48h later.  Once cell colonies 
were visible to the naked eye, colonies were picked and re-plated individually as 
independent cell lines stably expressing hNav1.2.  Cell lines stably expressing hNav1.2 
were maintained in maintenance media (1X DMEM, 10% FBS, 1% 
penicillin/streptomycin) containing 500 μg /mL G418. 
HEK Electrophysiology 
Currents were measured at room temperature (~22°C) using a HEKA EPC 10 
amplifier and the Pulse software (v8.80, HEKA Elektronik) for data acquisition.  
Electrodes were fabricated from 100 μL calibrated pipettes (Drummond Scientific 
Company, Broomall, PA; cat. # 2-000-100; capillary glass) and fire-polished to a 
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resistance of 1.0-2.0 MΩ using a P-1000 micropipette puller (Sutter Instrument 
Company, Novato, CA).  For each cell, a GΩ seal was obtained before breaking into the 
whole-cell configuration.  Voltage protocols were initiated five minutes after entering 
the whole-cell configuration, allowing time for each cell’s cytoplasm to equilibrate with 
the pipette solution, while also controlling for time-dependent shifts in sodium channel 
properties.  Voltage errors were minimized by using series resistance compensation (up 
to 90%), and passive leak currents were cancelled by P/-5 subtraction.  The bath 
solution contained (in mM):  140 NaCl, 3 KCl, 1 MgCl2, 1 CaCl2, and 10 HEPES, adjusted to 
pH 7.30 with NaOH.  The pipette solution contained (in mM):  130 CsF, 10 NaCl, 10 
HEPES, and 1 CsEGTA, adjusted to pH 7.30 with CsOH.  Navβ accessory subunits were 
not co-transfected with the Nav1.2α subunit, which functions independently as a 
channel, due to the variability that this would introduce into the experiments and the 
lack of information regarding which Navβ subunits are associated with the Nav1.2α 
subunits in the affected neurons in the brain.  When measuring resurgent currents, the 
Navβ4 peptide (KKLITFILKKTREK-OH, used at 200 μM) (Biopeptide Co., Inc., San Diego, 
CA), which corresponds to part of the C-terminal tail of the full-length Nav β4 subunit, 
was included in the pipette solution in order to induce the resurgent currents.  This 
peptide has been shown to induce resurgent currents in HEK cells expressing voltage-
gated sodium channels, while, for unknown reasons, the full-length Navβ4 protein is not 
sufficient to produce resurgent currents in HEK cells expressing voltage-gated sodium 
channels (Aman et al., 2009; Chen et al., 2008). 
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HEK Voltage Protocols 
All HEK cells were held at -100 mV. 
Measures pertaining to transient current size, voltage-dependent activation, and 
persistent current were taken from a voltage protocol consisting of 50 ms test pulses to 
voltages from -80 to +60 mV, in 5 mV steps (Fig. 5A) for mutation characterization 
experiments.  For pharmacology experiments, these values were derived from the first 
several sweeps in the inactivation protocol, which consisted of 500 ms hyperpolarizing 
pulses from -130 - +10 mV followed by a 20 ms depolarizing test pulse to +10 mV (Fig. 
5B).  Peak current amplitudes, for each voltage, were measured as the minimum value 
of the current over the entirety of the test pulse.  Current densities were calculated by 
dividing raw current amplitudes by the membrane capacitance value of each cell.  The 
reversal potential was estimated, for each cell, by extrapolation of the ascending limb of 
the current-voltage (IV) curve.  The conductance values were then calculated and 
normalized within each cell.  Persistent currents were measured, in Pulsefit (v8.80, HEKA 
Elektronik), as an average of the current amplitude over the last 10% of the test pulse, 
from 45-50 ms. 
As mentioned above, inactivation was measured by a 500 ms prepulse step to 
voltages from -130 to +10 mV, in 10 mV steps, followed by a 20 ms test pulse to +10 mV 
(Fig. 5B).  As with the activation protocol, peak transient current amplitude, for each 
voltage, was measured as the minimum value of the current over the entirety of the test 
pulse.   
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Resurgent currents were elicited by a 20-ms pulse to +30 mV, followed by a 50-
ms repolarization step of voltages from +10 to -65 mV (Fig. 5C).  The resurgent current 
peak amplitude was measured, in Pulsefit, as the largest inward current value elicited 
during the repolarization step.  For pharmacology experiments, in order to improve my 
confidence in the resurgent current values, each value was the average value from three 
repeats of each sweep. 
Gating pore currents were measured with the same voltage protocol that was 
used to measure transient current size (with the addition of TTX to the bath solution and 
the exclusion of Navβ4 peptide from the pipette solution).  The gating pore current 
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amplitude at each voltage step was measured as the average current amplitude from 1-
99% of the duration of the test pulse. 
Subcloning and Expression in Oocytes 
For expression of hNav1.2 in oocytes, the SCN2A gene was cut from the pcDNA3.1 
vector using the restriction enzymes NotI and NheI and subcloned into the pGEMHE-membrane-
mEGFP plasmid (a gift from Melina Schuh, Addgene plasmid #105526 ; 
http://n2t.net/addgene:105526; RRID:Addgene_105526; Clift et al., 2017), replacing the EGFP 
gene in that construct with the SCN2A gene.  The human β1 subunit, also in pGEMHE (Struyk 
and Cannon, 2007), was co-expressed with hNaV1.2 because it normalizes the inactivation 
kinetics of voltage-gated sodium channels expressed in Xenopus oocytes (Patton et al., 1994).  
Complementary RNAs were synthesized in vitro with the mMessage mMachine transcription kit 
(Ambion™).  Oocytes were injected with ~ 50 ng of the hNaV1.2 WT or R853Q transcript plus 50 
ng of the β1 subunit (four-fold molar excess). 
Oocyte Maintenance 
Oocytes were harvested from three female Xenopus laevis under MS222 
anesthesia, in accordance with the guidelines established by the University of California, 
Los Angeles animal care committee’s regulations. After defolliculation in collagenase 
type I at room temperature for ~ 2 h, oocytes were injected with cRNA and stored at 18 
oC in 0.5 x Leibovitz’s L-15 medium (Gibco™) supplemented with 1% horse serum, 100 
U/ml penicillin, 100 μg/ml streptomycin and 100 μg/ml amikacin. 
Oocyte Electrophysiology 
Currents were recorded 3-6 days after injection using a cut-open oocyte voltage-
clamp with the CA-1B amplifier (Dagan Corp.) in headstage clamp mode, as previously 
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described (Struyk and Cannon, 2007).  The extracellular solution (upper and middle 
chambers) contained in mM: 115 Na-methanesulfonate, 3 K-methanesulfonate, 4 Ca-
acetate, 10 HEPES, 0.1 ouabain, and 0.005 TTX, pH 7.4 with NaOH.  The internal solution 
(lower chamber) contained in mM: 120 K-methanesulfonate, 10 EGTA, 10 HEPES, pH 7.4 
with methanesulfonic acid.  The lower surface of the oocyte was permeabilized by brief 
exposure to internal solution supplemented with 0.1% saponin. 
Oocyte Voltage Protocols 
To record gating pore current, an oocyte was held at -100 mV and a series of 200 
ms voltage steps from -140 to +40 mV was applied.  No on-line leak subtraction was 
used.  Instead, a linear fit of the (total) steady-state IV for test potentials from -20 mV to 
+10 mV obtained to estimate the nonspecific linear current, which was subtracted to 
obtain the gating pore current (see Fig. 11).   Charge displacement current was recorded 
by application of a series of 20 ms test depolarizations from -140 mV to +40 mV from a 
holding potential of -100 mV.  The membrane capacitance was analog compensated 
with the amplifier circuitry, and the residual linear leakage current suppressed by P/N 
on-line leak subtraction of the current elicited by a depolarization from -120 mV to -100 
mV.  The charge displacement current was integrated digitally to obtain on-gating 
charge, Qon. 
Pharmacology Methods 
HEK293 cells stably expressing WT hNav1.2 channels were cultured in 
maintenance media (DMEM with 10% FBS and 1% penicillin/streptomycin) containing 
G418 (500 μg/mL).  Cells were used 2 days (36-52h.) after splitting.  The cells to be 
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studied were pre-incubated at 37°C for 15 minutes in either plain DMEM (untreated 
controls) or DMEM containing the pharmacological treatment (vehicle or vehicle + 
compound).  Following the preincubation, the DMEM media was removed and replaced 
with HEK bath solution (recipe provided in previous “HEK Electrophysiology” section).  
Vehicle and compound treatments were added to the bath solution for those groups, at 
the same concentrations as in the preincubation.   
Tested compounds included cannabidiol (CBD, Cayman Chemicals) and GS967 
(Cayman Chemicals).  Cannabidiol was dissolved in methanol at a stock concentration of 
1 mM and stored at -20°C.  GS967 was dissolved in dimethyl sulfoxide (DMSO) at a stock 
concentration of 1 mM and stored at -20°C.  Both compounds were used at 1 μM final 
concentrations.  Stock solutions were stored as 2 μL aliquots, one of which was diluted 
in each DMEM preincubation (2 mL) and each bath solution (2 mL) for each 35mm dish 
of cells, yielding a final solution comprised of 0.1% vehicle or compound solution.   
Since the pharmacology experiments investigated the compounds’ abilities to 
preferentially inhibit resurgent current over transient current, Navβ4 peptide (200 μM) 
was included in the pipette solution to induce resurgent currents.  
For these experiments, transient currents were measured as the peak transient 
current elicited by the inactivation protocol (Fig. 5B), and peak persistent currents were 
also measured as the average current over the last 10% of the depolarization test pulse 
(from 18-20 ms) from this protocol.  Peak resurgent currents were measured from the 
resurgent current protocol (Fig. 5C), as described above. 
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Statistics and Analysis 
Electrophysiological data were analyzed using Pulsefit (v.8.80, HEKA Elektronik), 
Microsoft Excel, Origin (v9.1, OriginLab Corp.), and GraphPad Prism (v.7.03, GraphPad 
Software, Inc.).  All data points are presented as mean ± standard error of the mean 
(SEM), and n is the number of cells from which contributing data was collected.  Current 
density and conductance were calculated as previously described (Cummins et al., 1994; 
also see subsection above entitled “HEK Cell Voltage Protocols”).  Activation and 
inactivation midpoints were estimated by fitting the current-voltage (IV) plot and 
inactivation curve for each cell to a current-voltage equation and the Boltzmann 
equation, repspectively, in Pulsefit.  Inactivation time constants were estimated by 
fitting the decay portion of each sodium current trace to a single-exponential equation 
in Pulsefit. 
The normality of data distribution was evaluated with the Shapiro-Wilk normality 
test.  If the data was normally distributed, a parametric test was used; if the data was 
not normally distributed, a nonparametric test was used.  For data comparisons 
spanning multiple voltages, a two-way ANOVA with the Sidak’s multiple comparisons 
test was used.  For single-measure comparisons between HEK cells expressing WT and 
L835F mutant channels, student’s t tests or Mann-Whitney (nonparametric) tests were 
used.  When a single measure was compared between the control and two conditional 
groups, as in the data comparing HEK cells expressing WT, R853Q mutant, and R1882Q 
mutant channels, and in the datasets comparing untreated cells with vehicle- and 
compound-treated cells, the data for all groups were collected concurrently, so these 
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single measurements were compared with one-way ANOVAs.  If the data was normally 
distributed, an ordinary one-way ANOVA with Dunnett’s multiple comparisons test was 
used; if the data was not normally distributed, the nonparametric Kruskal-Wallis with 
Dunn’s multiple comparisons test was used.  Statistical significance was set at α = 0.05.  
Unless otherwise stated, p values reported for ANOVAs are the p values obtained from 
the post-test, and a significant p value (p < 0.05) was obtained in the ANOVA test.  For 
all figures, unless otherwise specified, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p 
< 0.0001.  Data from oocytes only included two groups, wild-type and R853Q, and 
therefore a nonparametric Mann-Whitney test was used for the single-measure 
comparison of Qmax values obtained from oocytes. 
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III.  RESULTS 
To investigate the functional effects of the L835F, R853Q, and R1882Q mutations 
on hNav1.2 channel function, the biophysical properties of wild-type and mutant 
voltage-gated sodium channels were characterized using whole-cell voltage clamp 
electrophysiology. The channel constructs were transiently expressed in HEK cells, which 
I have found to express little to no endogenous voltage-gated sodium current (-207.1 ± 
33.64 pA, n = 10).  Therefore, most of the voltage-gated inward current that I see, 
which, on average, is many times the amplitude of the average endogenous current, can 
be attributed to the wild-type or mutant channels for which the DNA was transfected. 
 
Effects of the L835F Mutation on hNav1.2 Channel Function 
Compared to wild-type (WT), the L835F mutation did not significantly alter 
average peak transient current density elicited by voltage steps between -80 and +65 
mV (Fig. 6A-B, two-way ANOVA p = 0.0532, Sidak’s multiple comparisons p > 0.99 at all 
tested membrane potentials, n = 11 WT, 18 L835F), maximum peak transient current 
density (an average of the maximum peak transient current density values for individual 
cells, WT -0.43 ± 0.07 nA/pF, L835F -0.47 ± 0.06 nA/pF, n = 11 WT, 18 L835F; p = 0.5968), 
or the average maximum peak transient current amplitude (an average of the maximum 
peak transient current amplitude values for individual cells, WT -8.19 ± 1.34 nA, R853Q -
7.31 ± 0.92 nA, n = 12 WT, 16 L835F; p = 0.5785).  Thus, the L835F mutation has no 
effect on transient hNav1.2 current amplitudes or densities in HEK cells.   
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The voltage dependence of activation and inactivation were assessed using step 
depolarizations as seen in the voltage protocols (Fig. 5A-B).  The L835F mutation 
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produced depolarizing shifts in the voltage dependence of activation (Fig. 6C, two-way 
ANOVA p = 0.0004; Sidak’s multiple comparisons, p > 0.2500 at all tested membrane 
potentials), and the average estimated activation midpoint (WT -19.03 ± 3.10, L835F -
11.99 ± 2.41, n = 12 WT, 18 L835F; p = 0.0861) for hNav1.2 channels transiently 
expressed in HEK cells.  The L835F mutation did not significantly alter the voltage-
dependence of fast inactivation (Fig. 6D, two-way ANOVA p = 0.1404, n = 12 WT, 16 
L835F), the average estimated midpoint of inactivation (WT -53.98 ± 2.77 mV, L835F -
50.05 ± 2.14 mV, n = 12 WT, 17 L835F; p = 0.2636), or the kinetics of inactivation (Fig. 
6E, two-way ANOVA p = 0.0085; Sidak’s multiple comparisons p = 0.2946 - >0.9999 at all 
tested voltages).  Thus, the L835F mutation had only a small depolarizing effect on 
hNav1.2 activation and no effect on inactivation in HEK cells. 
The persistent component of the transient current was measured as the average 
current amplitude during the last 10% of each depolarization pulse in the activation 
protocol (Fig. 5A).   As shown in the representative traces (Fig. 7A), the L835F mutation 
increased the average inward persistent current densities at voltages positive to -35 mV 
(Fig. 7B, p = 0.0136 at -30 mV, p = 0.0336 at -20 mV, p < 0.01 from -15 - +10 mV, n = 11 
WT, 18 L835F).   This increase in persistent current was further supported by an increase 
in the average persistent current amplitude during the voltage step that elicited the 
peak transient current amplitude for each cell (WT -31.60 ± 7.54 pA, L835F -57.26 ± 5.21 
pA, n = 12 WT, 18 L835F; p = 0.0072; data not shown).  To normalize the persistent 
current amplitudes to overall expression levels, I also plotted persistent current 
amplitude as a percentage of the maximum peak transient current amplitude of the 
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cells (values calculated for individual cells, average values plotted in Fig. 7C).  This 
analysis revealed that the persistent current was increased by the L835F mutation at 
voltages positive to -35 mV, compared to persistent current in the wild-type channel 
(Fig. 7C, p = 0.0569 at +5 mV, p = 0.0002 at +10 mV).  Thus, the L835F mutation 
increased persistent hNav1.2 currents in HEK cells.  The effects of this mutation on 
resurgent currents has not been studied, but I would expect the increase in persistent 
currents to be accompanied by either no change or an increase in peak resurgent 
current density and/or in peak resurgent current expressed as a percentage of peak 
transient current.   
 The results of this experiment are reported in Table 2. 
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Effects of the R853Q Mutation on hNav1.2 Channel Function 
The R853Q mutation decreases transient current and enhances fast inactivation 
The experiments characterizing the R853Q and R1882Q mutations were not 
performed contemporaneously with the experiment characterizing the L835F mutation, 
so separate WT groups were used for the two sets of characterization experiments.  This 
way, the data from cells expressing each mutant was compared to contemporaneous 
data from cells expressing WT channels.  In the presence of the Navβ4 peptide in the 
pipette solution, the R853Q mutation decreased the average peak transient current 
density, compared to wild-type (Fig. 8A-B, p < 0.05 from -30 - +30 mV), as well as the 
average maximum peak transient current density (WT-0.55 ± 0.05 nA/pF, R853Q -0.28 ± 
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0.04 nA/pF, n = 40 WT, 15 R853Q; p = 0.0033).  The R853Q mutation also resulted in a 
reduction of maximum peak transient current amplitude (WT -8.75 ± 0.76 nA, R853Q -
3.82 ± 0.54 nA, n = 41 WT, 16 R853Q; p = 0.0045).  Thus, the R853Q mutation decreased 
transient hNav1.2 current amplitudes and densities in HEK cells. 
The same voltage protocols that were used to study activation and inactivation 
in the L835F mutant were used to study these parameters for the R853Q mutant (Fig. 
5A-B).  The R853Q mutation did not significantly alter the voltage-dependence of 
activation for hNav1.2 channels (Fig. 8C, p > 0.99 at all tested membrane potentials).  
This was supported by a lack of significant difference in average estimated activation 
midpoints (WT -26.5 ± 1.48, R853Q -25.11 ± 1.81, n = 41 WT, 16 R853Q; one-way 
ANOVA p = 0.79).  However, the mutation produced hyperpolarizing shifts in both the 
voltage-inactivation relationship (Fig. 8D, p = 0.0001 at -70 and -60 mV) and the average 
estimated inactivation midpoint (WT -65.01 ± 1.27 mV, R853Q -71.46 ± 1.62 mV, n = 40 
WT, 16 R853Q; p = 0.016).  The speed of fast inactivation, measured as a time constant, 
was unaltered by the R853Q mutation (Fig. 8E, p > 0.99 at all tested membrane 
potentials).  Thus, the R853Q mutation had no effect on hNav1.2 activation but 
enhances inactivation in HEK cells. 
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The R853Q mutation decreases persistent and resurgent currents 
Persistent current was measured in the same manner for the R853Q mutant 
channel as for the L835F mutant and wild-type channels.  As shown in the 
representative traces (Fig. 9A), the R853Q mutation reduced the average inward 
persistent current densities between voltages of -60 mV to +10 mV (Fig. 9B, p = 0.0028 – 
0.05 from -35 - +5 mV).  This reduction in persistent current was further supported by a 
reduction in the average persistent current amplitude during a -30-mV depolarization 
(WT -44.97 ± 4.15 pA, R853Q -12.78 ± 4.27 pA, n = 40 WT, 16 R853Q; p = 0.0008).  When 
normalized to the maximum peak transient current amplitudes for individual cells, the 
persistent current was reduced, though not significantly, by the R853Q mutation, 
compared to persistent current in the wild-type channel (Fig. 9C, p > 0.10 at all tested 
membrane potentials).  This reduction was supported by analysis of the average 
persistent current during a -30 mV step, as percent of peak transient current, which 
showed a significant reduction in this value with the R853Q mutation, compared to wild-
type (WT 0.57 ± 0.05 %, R853Q 0.26 ± 0.10, n = 40 WT, 16 R853Q; p = 0.037).  Thus, the 
R853Q mutation decreased persistent hNav1.2 currents in HEK cells. 
 
 54 
 
 55 
Resurgent sodium currents have not been studied with Nav1.2 disease 
mutations, though they have been associated with other diseases (Xiao et al., 2019, 
Jarecki et al., 2010, Hargus et al., 2011, Tanaka et al., 2016, Patel et al., 2016).  To induce 
resurgent current through Nav1.2 in HEK cells, the Navβ4 peptide (200 μM) was 
included in the pipette solution.  Cells were depolarized to +30 mV briefly, to open the 
channel and allow the peptide time to block the central pore, followed by a longer 
repolarization to voltages ranging from -65 to +10 mV (Fig. 5C; 9D, top).  Resurgent 
current occurs during the repolarization step, after the transient current is inactivated, 
when the peptide unbinds and a small inward current occurs between the unbinding of 
the peptide and the binding of the inactivation particle to the pore.  Compared to cells 
expressing wild-type hNav1.2 channels, cells expressing R853Q mutant channels 
exhibited a significant reduction in average resurgent current densities (Fig. 9D-E, p = 
0.0058 – 0.0137 from -40 - -30 mV), which also manifested as a reduction when the 
maximum peak resurgent current amplitudes were normalized to the maximum peak 
transient current amplitudes for individual cells (Fig. 9F, p = 0.0972 at -35 mV, p > 0.10 
at all other tested membrane potentials).  These results were supported by analysis of 
the average resurgent current amplitudes during a -30 mV pulse, which revealed a 
significant reduction in the average peak resurgent current amplitude (WT -178.40 ± 
15.33 pA, R853Q -61.33 ± 7.26, n = 39 WT, 16 R853Q; p < 0.0001) and a nearly-
significant reduction in the average peak resurgent current amplitude expressed as a 
percentage of peak transient current amplitude (WT 2.39 ± 0.18 %, R853Q 1.55 ± 0.11 
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%, n = 39 WT, 16 R853Q; p = 0.0389).  Thus, the R853Q mutation decreases resurgent 
hNav1.2 currents in HEK cells. 
The R853Q mutation forms a gating pore that passes current at negative membrane 
potentials 
All of my data up to this point suggests that the R853Q mutation confers a loss of 
function on the hNav1.2 channel.  Since the seizures and choreoathetosis (a specific 
form of irregular involuntary movements) associated with the R853Q mutation suggest 
a possible neuronal gain of function effect, I hypothesized that this mutation increases 
channel activity via the formation of a gating pore conductance.  Such a pore, which is 
structurally distinct from the central pore, can allow some monovalent cations to leak 
into the cell through the domain II voltage sensor, which contains the R853Q mutation 
(Fig. 4).   
To assess the effects of the R853Q mutation on the gating pore current, cells 
expressing wild-type or R853Q mutant hNav1.2 were treated with TTX and subjected to 
a series of voltage steps, in the absence of the Navβ4 peptide.  Such experiments in HEK 
cells yielded inconsistent results which were difficult to interpret.  Since Xenopus 
oocytes are much larger and can express more copies of the transfected Nav channel, 
the peak current amplitude in oocytes is much larger (~1,000x) than that recorded from 
HEK cells.  Due to the large magnitudes of currents in oocytes, including gating pore 
current, this expression system allows rigorous quantification of any differences in 
gating pore current amplitude between wild-type and R853Q mutant hNav1.2 channels.  
The optimized hNav1.2 wild-type and R853Q mutant channel constructs were subcloned 
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from the pcDNA3.1 vector into a pGEMHE vector that could be used for sodium channel 
expression in oocytes.  To estimate relative plasma membrane expression levels of wild-
type and R853Q mutant hNav1.2 channels, the average maximal gating charge (Qmax) of 
oocytes expressing wild-type or R853Q mutant hNav1.2 channels was measured in the 
presence of TTX.  The peak Qmax was significantly reduced by the R853Q mutation, 
compared to wild-type (Fig. 10A, WT 0.85 ± 0.12 nC, n = 5; R853Q 0.44 ± 0.06 nC, n = 6; 
p < 0.0001 at all voltages positive to 0 mV).  The magnitude of this reduction of Qmax 
(~50%) suggests that the plasma membrane expression level of the channels is reduced 
by the R853Q mutation, consistent with the reduced amplitude of the transient inward 
sodium current in HEK cells.  Normalizing the Q(V) curves to Qmax for each cell and 
plotting the average across cells revealed no significant change in the midpoint or slope 
of the gating charge-voltage relationship between wild-type -expressing and R853Q-
expressing oocytes (Fig. 10B).  The gating charge movement reflects the movement of 
the S4 (voltage-sensing) segments during activation, these results suggest that the 
R853Q mutation does not alter the voltage dependence of voltage sensor movement, 
with regards to activation.   
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To measure gating pore current, the total leak current in oocytes expressing 
wild-type or mutant hNav1.2 was measured over a range of membrane potentials (-120 
to +40 mV) in the presence of TTX, which blocked the central pore and prevented 
transient current conduction (see raw traces in Fig. 11A-B).  In order to isolate the gating 
pore current, the average nonspecific leak current was subtracted from the total leak 
current.  The average nonspecific leak was estimated by fitting the steady-state current-
voltage (I-V) curve (range -20 to + 10 mV, end of 200 ms pulse) with a line (Fig. 11C-D, 
dotted lines) and subtracted from the total leak current (11C-D, data points) to generate 
gating pore current I-V curves for oocytes expressing wild-type and R853Q channels (Fig. 
11E-F).  Compared to oocytes expressing wild-type channels, R853Q-expressing oocytes 
demonstrated an inwardly-rectifying current that diverges from the nonspecific leak 
current at hyperpolarized potentials (Fig. 11E-F).  This anomalous inward-rectifying 
current presumably exists due to the formation of a gating pore in the mutant channel, 
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as supported by dramatically increased current amplitude in the presence of 
extracellular guanidinium (Fig. 12), which has been reported for gating pore currents in 
R/X mutations of S4 in Nav1.4 (Sokolov et al., 2010).   
To further confirm that the inwardly-rectifying current in the R853Q mutant 
channels is conducted by the gating pore, and not an endogenous conductance, the 
Qmax for each cell was plotted against the measured gating pore current at -120 mV.  
This plot (Fig. 13A) revealed a linear correlation between inward current amplitudes and 
the corresponding maximal gating charge displacement in individual oocytes for the 
R853Q mutant channel (Pearson’s R = –0.974, R2 (adjusted) = 0.943), but not for the 
wild-type channel.  This suggests that a gating pore current that is dependent on 
channel density is present in the R853Q mutant form of hNav1.2 but essentially absent 
in the wild-type form.   
To facilitate the comparison of gating pore currents in oocytes with different 
levels of channel expression on the plasma membranes, leak-subtracted currents were 
normalized to Qmax for each oocyte.  The average normalized I-V relationships of wild-
type - and R853Q-expressing oocytes revealed a substantial increase in 
hyperpolarization-activated inward current in R853Q-expressing oocytes compared to 
wild-type -expressing oocytes (Fig. 13B).  These data provide strong support for the 
theory that a gating pore current exists in the R853Q mutant channel at membrane 
potentials negative to -30 mV.  
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Effects of the R1882Q Mutation on hNav1.2 Channel Function 
The R1882Q mutation impairs fast inactivation 
In HEK cells transiently expressing hNav1.2, and with the Navβ4 peptide in the 
pipette solution, the R1882Q mutation had no effect on the average peak transient 
current density (Fig. 14A-B, p > 0.40 at all tested membrane potentials).  It also had no 
effect on the average maximum peak transient current density (WT -0.55 ± 0.05 nA/pF, 
R1882Q -0.51 ± 0.07 nA/pF, n = 40 WT, 22 R1882Q; p = 0.80) or the average maximum 
peak transient current amplitude (WT -8.75 ± 0.76 nA, R1882Q -8.89 ± 1.14 nA, n = 41 
WT, 27 R1882Q; p > 0.99).  Thus, the R1882Q mutation did not alter transient hNav1.2 
current amplitudes or densities in HEK cells. 
The same voltage protocols that were used to study activation and inactivation 
in the previous two mutants were used to study these parameters for the R1882Q 
mutant (Fig. 5A-B).  The R1882Q mutation produced no significant shift in the 
conductance curve of Nav1.2, compared to wild-type (WT) (Fig. 14C, p > 0.40 at all 
tested membrane potentials) and had no effect on the average midpoint of activation 
(WT -26.50 ± 1.48 mV, R1882Q -24.77 ± 2.76 mV, n = 41 WT, 24 R1882Q; one-way 
ANOVA p = 0.79).  The R1882Q mutation produced a significant depolarizing shift in the 
fast inactivation curve (Fig. 14D, p = 0.0001 from -70 - -50 mV, p = 0.040 at -40 mV), 
which was reflected in the depolarization of the average inactivation midpoint (WT -
65.01 ± 1.27 mV, R1882Q -57.34 ± 2.05 mV, n = 40 WT, 20 R1882Q; p = 0.0017).  The 
R1882Q mutation also slowed inactivation, as evidenced by increased inactivation time 
constants at voltages from -20 to +10 mV (Fig. 14E, p < 0.0001 at -20 and -15 mV, p = 
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0.0185 at -10 mV).  Thus, the R1882Q mutation had no effect on hNav1.2 activation but 
impaired inactivation in HEK cells. 
The R1882Q mutation increases persistent and resurgent currents 
Persistent current was measured in the same manner for the R1882Q mutant 
channel as for the previous two mutants.  The R1882Q mutation increased average 
persistent current densities at voltages from -65 to +5 mV (Fig. 15A-B, p = 0.0001 from -
50 to -25 mV, p = 0.0016 at -20 mV, p = 0.0526 at -15 mV).  When analyzed at a single 
voltage of -30 mV, the average persistent current amplitude was increased for the 
R1882Q mutant, compared to wild-type (WT -44.97 ± 4.15 pA, R1882Q -100.80 ± 16.53 
pA, n = 40 WT, 27 R1882Q; p = 0.029).  When normalized to the maximum peak 
transient current amplitudes for individual cells, the persistent current was still 
increased for the R1882Q mutant channel at most voltages from -65 to +5 mV (Fig. 15C, 
p < 0.05 from -35 to -20 mV), compared to the wild-type channel.  When the persistent 
current, as percent of transient current, was analyzed at -30 mV, the significant increase 
caused by the R1882Q mutation was again observed (WT 0.57 ± 0.05 %, R1882Q 1.15 ± 
0.13, n = 40 WT, 27 R1882Q; p < 0.0001).  Thus, the R1882Q mutation enhanced 
persistent hNav1.2 currents in HEK cells. 
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Resurgent current was measured in the same manner for the R1882Q mutant 
channel as for the R853Q mutant and wild-type channels (protocol in Fig. 5C and 15D, 
top).  The R1882Q mutation increased average resurgent current densities at voltages 
from -65 to 0 mV (Fig. 15D, E, p = 0.0082 – 0.046 from -35 - -20 mV).  When analyzed at 
a single voltage of -30 mV, the average maximum resurgent current amplitude was 
increased for the R1882Q mutant, compared to wild-type (WT -178.40 ± 15.33 pA, 
R1882Q -284.80 ± 45.71 pA, n = 39 WT, 25 R1882Q; Kruskal-Wallis test, p < 0.0001, 
Dunn’s multiple comparisons test, WT vs. R1882Q, p = 0.3432).  When the resurgent 
current, as percent of transient current, was analyzed at -30 mV, the R1882Q mutation 
still increased the value, compared to wild-type (WT 2.39 ± 0.18 %, R1882Q 3.35 ± 0.31 
%, n = 39 WT, 25 R1882Q; p = 0.0050).  When normalized to the maximum peak 
transient current amplitudes for individual cells, the resurgent current was, again, 
increased by the R1882Q mutation at voltages from -65 to -5 mV (Fig. 15F, p = 0.0053 – 
0.0446 from -35 - -20 mV). Thus, the R1882Q mutation enhanced hNav1.2 resurgent 
currents in HEK cells. 
The results of this experiment, encompassing the R853Q and R1882Q mutations, 
are reported in Table 3. 
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Transient Transfections without Navβ4 Peptide 
In order to strengthen my confidence that the observed effects of the mutations 
that I observed in HEK cells transiently transfected with the hNav1.2 channels was not 
due to the presence of Navβ4 peptide, I repeated the characterization experiments with 
HEK cells transiently expressing WT, R853Q mutant, or R1882Q mutant hNav1.2, in the 
absence of the peptide.   
Effects of the R853Q Mutation in the Absence of Navβ4 
 In the absence of the Navβ4 peptide, the R853Q mutation reduced the average 
maximum peak transient current density of hNav1.2 in transiently transfected cells, 
though the decrease was not significant (WT -0.62 ± 0.08 nA/pF, R853Q -0.34 ± 0.07 
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nA/pF; n = 18 WT, 9 R853Q; ANOVA p = 0.0686); and it significantly reduced the average 
maximum peak transient current amplitude (WT -10.40 ± 1.30 nA, R853Q -5.08 ± 1.01 
nA; Dunn’s multiple comparisons, WT vs. R853Q p = 0.0298).  The R853Q mutation 
produced slight, but not significant shifts in the average estimated midpoint of 
activation (WT -20.03 ± 1.70 mV, R853Q -16.55 ± 2.42 mV; ANOVA p = 0.4086) and the 
average estimated midpoint of inactivation (WT -56.83 ± 1.55 mV, R853Q -60.53 ± 1.58 
mV; Dunn’s multiple comparisons, WT vs. R853Q p = 0.3269).  Thus, the R853Q 
mutation decreased transient currents, slightly depolarized the activation-voltage 
relationship, and slightly hyperpolarized the inactivation-voltage relationship in HEK 
cells transiently expressing hNav1.2 in the absence of the Navβ4 peptide. 
 The R853Q mutation slightly reduced, but did not significantly alter, the average 
maximum peak persistent current amplitude (WT -74.80 ± 13.00 pA, R853Q -47.06 ± 
5.30 pA; Dunn’s multiple comparisons, WT vs. R853Q p = 0.4632) and slightly increased, 
but did not significantly alter, the average maximum peak persistent current amplitude 
expressed as a percentage of the average maximum peak transient current amplitude of 
each cell (WT 0.74 ± 0.10 %, R853Q 1.22 ± 0.20 %; Dunn’s multiple comparisons, WT vs. 
R853Q p = 0.0626).  Thus, the R853Q mutation did not appreciably alter persistent 
currents in HEK cells transiently expressing hNav1.2 in the absence of the Navβ4 
peptide. 
Effects of the R1882Q Mutation in the Absence of Navβ4 
 In the absence of the Navβ4 peptide, the R1882Q mutation increased the 
average maximum peak transient current density of hNav1.2 in transiently transfected 
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cells, though the increase was not significant (WT -0.62 ± 0.08 nA/pF, R1882Q -0.90 ± 
0.26 nA/pF; n = 18 WT, 6 R1882Q; ANOVA p = 0.0686); and it did not alter the average 
maximum peak transient current amplitude (WT -10.40 ± 1.30 nA, R1882Q -13.97 ± 4.41 
nA; Dunn’s multiple comparisons, WT vs. R1882Q p > 0.9999).  The R1882Q mutation 
did not alter the average estimated midpoint of activation (WT -20.03 ± 1.70 mV, 
R1882Q -19.80 ± 1.34 mV; ANOVA p = 0.4086) but produced a significant depolarizing 
shift in the average estimated midpoint of inactivation (WT -56.83 ± 1.55 mV, R1882Q -
50.38 ± 0.67; Dunn’s multiple comparisons, WT vs. R1882Q p = 0.0217).  Thus, the 
R1882Q mutation did not significantly alter transient currents or the activation-voltage 
relationship, but it depolarized the inactivation-voltage relationship in HEK cells 
transiently expressing hNav1.2 in the absence of the Navβ4 peptide. 
 The R1882Q mutation slightly increased, but did not quite significantly alter, the 
average maximum peak persistent current amplitude (WT -74.80 ± 13.00 pA, R1882Q -
176.90 ± 53.18 pA; Dunn’s multiple comparisons, WT vs. R1882Q p = 0.0620) and 
significantly increased the average maximum peak persistent current amplitude 
expressed as a percentage of the average maximum peak transient current amplitude of 
each cell (WT 0.74 ± 0.10 %, R1882Q 1.38 ± 0.21 %; Dunn’s multiple comparisons, WT vs. 
R1882Q p = 0.0113).  Thus, the R1882Q mutation increases persistent currents in HEK 
cells transiently expressing hNav1.2 in the absence of the Navβ4 peptide. 
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Effects of the R853Q and R1882Q Mutations in Cell Lines Stably Expressing hNav1.2 
In order to strengthen my confidence in the observed effects of the mutations 
that I observed in HEK cells transiently transfected with the hNav1.2 channels, I 
repeated the characterization experiments with HEK cell lines stably expressing WT, 
R853Q mutant, or R1882Q mutant channels.  All three cell lines were studied in the 
absence of the Navβ4 peptide, and the WT and R1882Q cell lines were studied in 
additional experiments with the Navβ4 peptide in the pipette solution in order to 
examine the effects of the R1882Q mutation on resurgent current in cells stably 
expressing the mutant channels.  The experiment examining cell lines stably expressing 
hNav1.2 in the absence of the Navβ4 peptide were not contemporaneous with the other 
three experiments (transiently transfected cells with the Navβ4 peptide, transiently 
transfected cells without the peptide, and cell lines stably expressing hNav1.2 with the 
peptide). 
Effects of the R853Q Mutation on INa in Cell Lines Stably Expressing hNav1.2 
 The R853Q mutation significantly reduced peak transient current densities from -
20 to +40 mV (p = 0.0001 – 0.0454, fig. 16A) and maximum peak transient current 
density (WT -0.65 ± 0.05 nA/pF; R853Q -0.41 ± 0.04 nA/pF; p = 0.0029) in HEK cells 
stably expressing the mutant channel, compared to cells stably expressing the WT 
channel.  It also significantly decreased maximum peak transient current amplitude (WT 
-11.02 ± 0.77 nA, R853Q -8.351 ± 0.72 nA, n = 23 WT, 27 R853Q; p = 0.0414). The 
mutation did not significantly alter the voltage dependence of activation (p > 0.10 at all 
measured voltages; fig. 16B) or the estimated activation midpoint (WT -23.52 ± 0.92; 
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R853Q -24.16 ± 0.76; ANOVA p = 0.5172).  It did, however, produce a hyperpolarizing 
shift in the voltage dependence of fast inactivation (p = 0.0001 from -70 to -50 mV; fig. 
16C) and the estimated midpoint of inactivation (WT -56.31 ± 0.87 mV; R853Q -63.1 ± 
0.79 mV; p < 0.0001).  The speed of fast inactivation, as evidenced by the inactivation 
constants from -15 to 0 mV, was unaltered by the R853Q mutation (p > 0.87 at all 
measured voltages; fig. 16D).  Thus, the R853Q mutation does not alter the voltage 
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dependence of activation or the speed of fast inactivation in HEK cells stably expressing 
R853Q mutant hNav1.2 channels; though it does decrease transient current amplitudes 
and densities and produce a hyperpolarizing shift in the voltage dependence of fast 
inactivation.   
 The R853Q mutation significantly decreased the average maximum peak 
persistent current amplitude (WT -88.81 ± 10.83 pA; R853Q -62.62 ± 7.70 pA; p =0.0345) 
but did not significantly alter the average maximum peak persistent current measured 
as percentage of peak transient current (WT 0.958 ± 0.19%; R853Q 0.89 ± 0.12%; p > 
0.9999).  Thus, the R853Q mutation slightly reduces persistent currents in HEK cells 
stably expressing R853Q mutant hNav1.2 channels, compared to cells stably expressing 
WT channels. 
Effects of the R1882Q Mutation on INa in Cell Lines Stably Expressing hNav1.2 
In the absence of the Navβ4 peptide, the R1882Q mutation significantly 
increased the peak transient current densities, compared to WT, from -15 to +5 mV (Fig. 
16A, p = 0.0111 – 0.0442), though it does not significantly alter the maximum peak 
transient current density (WT -0.6504 ± 0.05 nA/pF; R1882Q -0.8081 ± 0.10 nA/pF; p = 
0.5148) or the maximum peak transient current amplitude (WT -11.02 ± 0.77 nA, 
R1882Q -13.73 ± 1.80 nA, n = 23 WT, 13 R1882Q; p = 0.6221).  The R1882Q mutation 
does not significantly shift the voltage dependence of activation (Fig. 16B, p = 0.0900 at 
-30 mV, p = 0.0529 at -25 mV, p > 0.500 at all other measured voltages) or the estimated 
midpoint of activation (WT -23.52 ± 0.92; R1882Q -22.48 ± 1.35; ANOVA p = 0.5172).  
The R1882Q mutation did, however, produce a depolarizing shift in the voltage 
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dependence of fast inactivation (Fig. 16C, p = 0.0001 – 0.0010 from -40 to -70 mV) and 
the estimated midpoint of inactivation (WT -56.31 ± 0.87 mV; R1882Q -46.59 ± 1.06 mV; 
p < 0.0001).  The speed of fast inactivation, as evidenced by the inactivation constants 
from -15 to 0 mV, was significantly increased by the R1882Q mutation (Fig. 16D, p = 
0.0001 at all measured voltages).  Thus, the R1882Q mutation does not alter the voltage 
dependence of activation but impairs inactivation in HEK cells stably expressing the 
mutant channel, compared to cells stably expressing the WT channel. 
 The R1882Q mutation significantly increased the average maximum peak 
persistent current amplitude (WT -88.81 ± 10.83 pA; R1882Q -289.0 ± 36.71 pA; p = 
0.0007) and the average maximum peak persistent current measured as percentage of 
peak transient current (WT 0.958 ± 0.19%; R1882Q 2.131 ± 0.08%; p = 0.0003).  Thus, 
the R1882Q mutation significantly increases persistent currents in HEK cells stably 
expressing R1882Q mutant hNav1.2 channels, compared to cells stably expressing WT 
channels. 
Effects of the R1882Q Mutation on INa in Cell Lines Stably Expressing hNav1.2 in the 
Presence of the Navβ4 Peptide 
 Since the R1882Q mutation increased INaR density in HEK cells transiently 
expressing R1882Q mutant hNav1.2 channels, compared to cells transiently expressing 
the WT channel, I investigated whether this enhancement of resurgent current and the 
other effects of the R1882Q mutation could be observed in HEK cells stably expressing 
the mutant channel.  Compared to cells stably expressing the WT channel, cells 
expressing the R1882Q mutant channel exhibited a slight decrease in the average 
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maximum peak transient current density (WT -0.947 ± 0.14 nA/pF, n = 13; R1882Q -
0.779 ± 0.06 nA/pF, n = 14; p = 0.2756) and no change in the estimated midpoint of 
activation (WT -32.58 ± 1.32 mV; R1882Q -30.47 ± 1.65 mV; p = 0.3298) in the presence 
of the Navβ4 peptide.  It did, however, cause a significant depolarizing shift in the 
estimated midpoint of inactivation (WT -63.17 ± 1.33 mV; R1882Q -54.13 ± 1.30 mV; p = 
0.0001).  Thus, in the presence of the Navβ4 peptide, the R1882Q mutation does not 
alter the voltage dependence of activation but impairs inactivation in HEK cells stably 
expressing the mutant channel, compared to cells stably expressing the WT channel. 
The R1882Q mutation also significantly augmented the maximum peak 
persistent current amplitude (WT -141.9 ± 21.01 pA; R1882Q -239.1 ± 24.63 pA; p = 
0.0027) and the maximum peak persistent current measured as a percentage of 
maximum peak transient current amplitude (WT 0.95 ± 0.17%; R1882Q 1.72 ± 0.06%; p = 
0.0040).  There was no difference in maximum peak resurgent current amplitude (WT -
382.7 ± 43.6 pA; R1882Q -368.4 ± 33.4 pA; p = 0.9362) or peak resurgent current 
normalized to maximum peak transient current amplitude (WT 2.414 ± 0.32 %; R1882Q 
2.723 ± 0.31 %; p = 0.5743).  Thus, in the presence of the Navβ4 peptide, the R1882Q 
mutation significantly increases persistent currents in HEK cells stably expressing 
R1882Q mutant hNav1.2 channels, compared to cells stably expressing WT channels. 
 
Pharmacology:  Targeting INaR over INaT 
 In order to begin identifying compounds that slectively inhibit persistent (INaP) 
and resurgent (INaR) sodium currents over transient sodium current (INaT), studies 
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involving two compounds (CBD and GS967) were performed. Epilepsy mutations in both 
SCN8A and SCN2A have now been shown to increase INaR.  Since our lab has shown that 
the enhancement of resurgent current by the SCN8A/Nav1.6 epilepsy mutation N1768D 
can be preferentially inhibited by CBD (Patel et al., 2016), I tested the ability of these 
compounds to preferentially inhibit INaR in the Nav1.2 channel isoform.  I tested the 
effects of these compounds in cells stably expressing hNav1.2 in the presence of the 
Navβ4 peptide.   
Cannabidiol (CBD) Effects on INaT, INaR, and INaP 
 Since CBD has been shown to inhibit the enhancement of INaR caused by the 
Nav1.6 epilepsy mutation N1768D without disturbing the INaT density (Patel 2016), I 
predicted that CBD would also preferentially inhibit INaR and/or INaP over INaT in HEK 
cells stably expressing WT Nav1.2.  Compared to untreated cells, methanol had no effect 
on average maximum peak transient current amplitude (untreated -12.53 ± 1.19 nA, n = 
9; vehicle (methanol) -12.28 ± 1.31 nA, n = 7; ANOVA p = 0.6805, data not shown) or 
average maximum peak transient current density (Fig. 17A, untreated -0.67 ± 0.06 
nA/pF, n = 9; vehicle (methanol) -0.68 ± 0.06 nA/pF; ANOVA p = 0.3591).  CBD (1 μM) 
had no significant effect on average maximum peak transient current amplitude (-10.54 
± 1.24 nA, n = 8, data not shown) or average maximum peak transient current density 
(Fig. 17A, -0.54 ± 0.07 nA/pF, n = 8) compared to untreated or methanol-treated cells 
(ANOVA p = 0.3591).  However, when the current densities were averaged within groups 
at each tested membrane potential, CBD significantly inhibited the transient current 
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density, compared to vehicle, from -45 to -35 mV (Fig. 17B, vehicle vs. CBD p < 0.05 from 
-45 to -25 mV, two-way ANOVA p < 0.0001).  Therefore, these data suggest that CBD (1 
μM) does not significantly reduce maximum peak transient current density, but it does 
inhibit average current density (compared to vehicle) from -45 to -25 mV in HEK cells 
stably expressing WT hNav1.2 channels. 
 Average maximum peak resurgent current densities were unaltered by methanol 
(Fig. 17C, untreated -23.79 ± 2.52 pA/pF, vehicle (methanol) -19.93 ± 2.37 pA/pF, p > 
0.9999) but significantly reduced by 1 μM CBD (Fig. 17C, CBD -8.07 ± 1.08 pA/pF; CBD vs. 
vehicle (methanol), p = 0.0137; CBD vs. untreated, p = 0.0005).  When the resurgent 
current densities were averaged at each tested membrane potential, I observed a 
significant reduction of average peak resurgent current densities by methanol (Fig. 17D, 
vehicle (methanol) vs. untreated, p = 0.0533 at -55 mV, p = 0.0055 - 0.0274 at all other 
measured voltages from -35 to -65 mV) and a further reduction by CBD (Fig. 17D, CBD 
vs. vehicle (methanol), p = < 0.0001 - 0.0120 from -20 to -55 mV; CBD vs. untreated, p = 
< 0.0001 - 0.0305 from -20 to -80 mV).  Therefore, resurgent current is moderately 
reduced by methanol and significantly reduced by 1 μM CBD in HEK cells stably 
expressing WT hNav1.2 channels.  
 The peak persistent current density was not significantly reduced by methanol 
(Fig. 17E, untreated -6.55 ± 1.29 pA/pF, vehicle (methanol) -4.54 ± 0.67 pA/pF, ANOVA p 
= 0.0727) and was slightly reduced by CBD (Fig. 17E, CBD -3.38 ± 0.39 pA/pF, ANOVA p = 
0.0727).  Thus, methanol and 1 μM CBD may moderately inhibit persistent current in 
HEK cells stably expressing WT hNav1.2 channels.   
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GS967 Effects on INaT, INaR, and INaP 
 Compared to untreated cells, the vehicle (DMSO) had no effect on average 
maximum peak transient current amplitude (untreated -11.84 ± 1.31 nA, n = 12; vehicle 
(DMSO) -11.33 ± 1.36 nA, n = 11; ANOVA p = 0.1011) or average maximum peak 
transient current density (Fig. 18A, untreated -0.62 ± 0.07 nA/pF, vehicle (DMSO) -0.63 ± 
0.06 nA/pF; ANOVA p = 0.0685).  GS967 (1 μM) slightly reduced average maximum peak 
transient current amplitude (-8.37 ± 0.47 nA, n = 10, ANOVA p = 0.1011) and average 
maximum peak transient current density (Fig. 18A, -0.46 ± 0.02 nA/pF) compared to 
untreated or methanol-treated cells (ANOVA p = 0.0685).  However, when the current 
densities were averaged within groups at each tested membrane potential, GS967 
significantly inhibited the transient current density, compared to vehicle, from -40 to 
+10 mV (Fig. 18B, p = 0.0145 at -40 mV, p < 0.0001 from -35 - +5 mV, p = 0.0003 at +10 
mV).  Therefore, these data suggest that GS967 (1 μM) does not significantly reduce 
maximum peak transient current density, but it does inhibit average current density 
(compared to vehicle) at voltages positive to -45 mV in HEK cells stably expressing WT 
hNav1.2 channels. 
 Average maximum peak resurgent current densities were unaltered by DMSO 
(Fig. 18C, untreated -18.16 ± 2.09 pA/pF, vehicle (DMSO) -19.15 ± 3.29 pA/pF; ANOVA p 
= 0.1193) and only slightly reduced by 1 μM GS967 (Fig. 18C, GS967 -12.35 ± 1.03 pA/pF; 
ANOVA p = 0.1193).  When the resurgent current densities were averaged at each 
tested membrane potential, I observed that DMSO did not alter average peak resurgent 
current densities (Fig. 18D, vehicle (DMSO) vs. untreated, p > 0.5000 at all 
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tested voltages).  Compared to vehicle (DMSO), GS967 significantly inhibited resurgent 
current densities from -50 to -25 mV (Fig. 18D, GS967 vs. vehicle (DMSO), p = 0.0003 - 
0.0326 from -20 to -55 mV).  Therefore, resurgent current is not affected by DMSO and 
moderately reduced by 1 μM GS967 in HEK cells stably expressing WT hNav1.2 channels.  
 The peak persistent current density was not significantly reduced by DMSO (Fig. 
18E, untreated -4.64 ± 0.54 pA/pF, vehicle (DMSO) -4.53 ± 0.58 pA/pF, p > 0.9999) and 
was significantly reduced by GS967 (Fig. 18E, GS967 -2.69 ± 0.46 pA/pF, GS967 vs. 
vehicle (DMSO) p = 0.0425).  Thus, while persistent current in HEK cells stably expressing 
WT hNav1.2 channels is apparently unaffected by DMSO, it is significantly inhibited by 1 
μM GS967.   
Cannabidiol (CBD) Effects on hNav1.2 Gating 
 In order to better understand how CBD and GS967 inhibit hNav1.2 currents, I 
examined the effects of these compounds on the voltage dependence of activation and 
inactivation.   
The vehicle for CBD, methanol, did not alter the conductance-voltage 
relationship (Fig. 19A, Tukey’s multiple comparisons, vehicle vs. untreated, p = 0.3931 at 
-40 mV, p > 0.9000 at all other tested voltages) or the average estimated midpoint of 
activation (Fig. 19B, untreated -40.14 ± 0.48 mV, vehicle -39.78 ± 1.69 mV, Dunn’s 
multiple comparisons, vehicle vs. untreated, p > 0.9999).  CBD elicited a depolarizing 
shift in the voltage dependence of activation, as evidenced by depolarizing shifts in the 
conductance-voltage relationship (Fig. 19A, CBD vs. vehicle, p = < 0.0001 – 0.0173 from -
40 to -25 mV) and in the average estimated 
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midpoint of activation (Fig. 19B, CBD -33.32 ± 2.21 mV, Dunn’s multiple comparisons, 
CBD vs. vehicle, p = 0.1534).  Though the shift in the average estimated midpoint of 
activation was insignificant when compared to the vehicle group, it was significant when 
compared to the untreated group (Dunn’s multiple comparisons, CBD vs. untreated, p = 
0.0069; vehicle vs. untreated, p > 0.9999).  Thus, CBD produces a depolarizing shift in 
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the voltage dependence of activation for WT hNav1.2 channels stably expressed in HEK 
cells. 
 Neither the vehicle or CBD produced any shift in the voltage dependence of 
inactivation, as evidenced by the absence of any shift in the inactivation-voltage 
relationship (Fig. 19C, two-way ANOVA p = 0.4304) or in the average estimated midpoint 
of inactivation (Fig. 19D, untreated -67.34 ± 0.93 mV, vehicle -66.11 ± 1.30 mV, CBD -
65.9 ± 1.39 mV, p = 0.6159).  Thus, CBD does not alter the voltage dependence of 
inactivation for WT hNav1.2 channels stably expressed in HEK cells.   
GS967 Effects on hNav1.2 Gating 
 The vehicle for GS967, DMSO, significantly depolarized the conductance-voltage 
relationship (Fig. 20A, Tukey’s multiple comparisons, vehicle (DMSO) vs. untreated, p < 
0.001 from -45 - -35 mV) but only mildly depolarized the average estimated midpoint of 
activation (Fig. 20B, untreated -41.15 ± 1.97 mV, vehicle (DMSO) -35.92 ± 1.53 mV, 
Dunn’s multiple comparisons, vehicle (methanol) vs. untreated, p = 0.0648).  Compared 
to vehicle (DMSO), GS967 did not shift the voltage dependence of activation, as 
evidenced by the absence of any shift in the conductance-voltage relationship (20A, 
GS967 vs. vehicle (DMSO), p = 0.2332 – 0.8550 from -50 - -35 mV, p > 0.9000 at all other 
tested voltages) and in the average estimated midpoint of activation (Fig. 20B, GS967 -
37.30 ± 1.16 mV, Dunn’s multiple comparisons, GS967 vs. vehicle (DMSO), p > 0.9999).  
Thus, while DMSO produces a depolarizing shift in the voltage dependence of activation, 
GS967 has no effect on the voltage dependence of activation for WT hNav1.2 channels 
stably expressed in HEK cells. 
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 The vehicle (DMSO) did not shift the voltage dependence of inactivation, 
compared to untreated cells, as evidenced by the absence of any shift in the 
inactivation-voltage relationship (Fig. 20C, Tukey’s multiple comparisons, vehicle 
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(DMSO) vs. untreated, p = 0.1492 – 0.8390 from -80 - -60 mV, p > 0.9000 at all other 
tested voltages) or in the average estimated midpoint of inactivation (Fig. 20D, 
untreated -67.41 ± 1.10 mV, vehicle (DMSO) -66.42 ± 0.87 mV, Dunn’s multiple 
comparisons, vehicle (DMSO) vs. untreated, p = 0.7543).  GS967 produced a 
hyperpolarizing shift in the voltage dependence of inactivation, as evidenced by 
hyperpolarizing shifts in the inactivation-voltage relationship (Fig. 20C, Tukey’s multiple 
comparisons, GS967 vs. vehicle (DMSO), p < 0.001 from -100 mV- -60 mV) and in the 
average estimated midpoint of inactivation (Fig. 20D, GS967 -78.77 ± 0.97 mV, Dunn’s 
multiple comparisons, GS967 vs. vehicle (DMSO), p < 0.0001).  Thus, GS967 produces a 
hyperpolarizing shift in the voltage dependence of inactivation for WT hNav1.2 channels 
stably expressed in HEK cells.    
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IV.  DISCUSSION 
Mutations in neuronal voltage-gated sodium channel isoforms are increasingly 
being identified as underlying otherwise idiopathic cases of epilepsy.  Though over 250 
different mutations in the Nav1.2 gene, SCN2A, have been reported as likely causes of 
epilepsy, biophysical characterization of only 21 of these mutations have been studied 
in vitro.  Nine have been shown to have only gain-of-function effects, six have primarily 
loss-of-function effects, and six have mixed gain- and loss-of-function effects (not 
including the mutations in this study).  However, our study (work published in Mason et 
al., 2019, available at https://www.eneuro.org/content/6/5/ENEURO.0141-19.2019) is 
the first to identify enhanced resurgent currents and gating pore currents as effects of 
SCN2A disease mutations.   
The L835F mutation has been identified in the SCN2A gene of a patient with 
severe epilepsy and is not found in healthy control genomes; therefore it is suspected to 
be an epileptogenic mutation.  Among the SCN2A mutations suspected to cause 
epilepsy in human patients, R853Q and R1882Q are two of the most commonly 
reported mutations (Wolff et al., 2017).  The R853Q mutation was identified in patients 
who were diagnosed with West Syndrome or unspecified epileptic encephalopathy.  
Most or all of these patients had late onsets of seizures (6 mos. – 3 yrs.); and many 
exhibit dystonia and/or choreoathetosis (Allen et al., 2013; Nakamura et al., 2013; 
Samanta and Ramakrishnaiah, 2015; Kobayashi et al., 2016; Wolff et al., 2017).  In 
contrast, the R1882Q mutation has been reported in numerous patients diagnosed with 
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early onset epileptic encephalopathies (6/7 reported onset of 1 day) (Carvill et al., 2013; 
Howell et al., 2015; Trump et al., 2016; Wolff et al., 2017).   
L835F Mutation Effects on hNav1.2 Function and Predicted Effects on Neuronal 
Excitability 
 Very little is known about the L835F mutation so far.  This leucine residue is in 
the third transmembrane segment (S3) of domain II (DII), which is believed to be 
clustered with S1, S2, and S4 in the tertiary structure of the channel.  Leucine and 
phenylalanine are both nonpolar residues, and their structures are closely related.  
Phenylalanine contains a benzene ring where leucine contains a dimethyl group, making 
phenylalanine larger.  This increase in size, despite the retention of nonpolarity at this 
position, may affect the residue’s interactions within the protein or with lipids in the 
surrounding membrane.  If this substitution produces such an alteration in interactions 
with nearby residues or molecules, then it may alter the protein conformation.  Since 
the mutation significantly enhances persistent current, it may destabilize the inactivated 
conformation of the channel or indirectly disrupt interactions between the inactivation 
particle and the central pore.  It is also possible that the L835F mutation acts in tandem 
with another genetic variant in another gene/protein to create a net effect of neuronal 
hyperexcitability that underlies this patient’s seizures.   Several studies have 
demonstrated that alterations in expression levels of other genes can alter seizure 
susceptibility and severity in rodents, including mouse models of SCN1A and SCN2A 
epilepsy (Jorge et al., 2011; Miller et al., 2014; Hawkins & Kearney, 2016; Lamar et al., 
2017, Follwaczny et al., 2017; Calhoun et al., 2017; Hawkins et al., 2019), and one 
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pharmacogenetics study suggested that a pair of particular single nucleotide 
polymorphisms (SNPs, i.e. variants) in the SCN2A and ABAT (which encodes GABA-T, a 
protein that catalyzes GABA) genes is correlated with the efficacy of valproate 
treatment in epileptic patients (Li et al., 2016).  Therefore, L835 and a variant of another 
gene may increase seizure susceptibility individually, and these effects could be additive 
or synergistic when both variants are present. 
If the non-significant shifts in the voltage dependencies of activation and 
inactivation are taken into account as effects of the L835F mutation, the slight 
depolarization of the activation midpoint (+7 mV) may overpower the slight 
depolarization of the inactivation midpoint (+4 mV) to decrease the window current 
(not analyzed in this study) and thus confer a net slight loss of function on the channel.  
This slight loss of function would probably be outweighed by the gains of function 
represented by the significant increase in persistent current and the slight slowing of 
inactivation (evidenced by slightly larger inactivation constants), which both aberrantly 
augment the sodium current through the channel.  Since enhancement of persistent 
currents is strongly associated with neuronal hyperexcitability, and the only significant 
difference the L835F mutation confers on the hNav1.2 channel in HEK cells is an 
increase in persistent current, this mutation is expected to cause affected neurons to be 
hyperexcitable.   
Enhancements in persistent currents are associated with increases in resurgent 
current and neuronal excitability, though it is unknown whether these effects 
accompany the increase in persistent current caused by the L835F mutation.  Also, given 
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that L835F is proximal to the region in which gating pores have been suggested to occur, 
there is a possibility that the L835F mutation affects the local channel conformation to 
create a gating pore.  The potential effect of this mutation on resurgent current and the 
possibility that it creates a conducting gating pore have not been investigated.  It is likely 
that this dissertation work has revealed only part of the full spectrum of biophysical 
effects of the L835F mutation on Nav1.2 channel function.  Further evidence suggesting 
that the L835F mutation causes a net gain of function in Nav1.2 channel function and 
hyperexcitability in affected neurons is needed to confirm the pathogenicity of this 
mutation. 
 
R853Q Mutation Effects on hNav1.2 Function and Predicted Effects on Neuronal 
Excitability 
A 2018 study of SCN2A mutations utilizing  Chinese hamster ovary (CHO) cells 
transiently transfected with hNav1.2 reported that the R853Q mutation in the human 
Nav1.2 channel decreases peak transient current density and produces a 
hyperpolarizing shift in the voltage dependence of inactivation (Berecki et al.); these 
observations were corroborated in this present study using HEK cells.  The data 
presented in Figure 9 also suggested that the R853Q mutation reduces persistent and 
resurgent currents.  The reductions in Qmax in oocytes and in current density in HEK cells 
resulting from the R853Q mutation, compared to the wild-type channel, suggest that 
this mutation reduces the surface expression of the channel.  All of these are loss-of-
function effects, which are predicted to decrease neuronal excitability.  Though loss of 
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Nav1.2 function is common among late-onset SCN2A epilepsies, it is unclear how loss of 
function in Nav1.2, which is predicted to decrease the excitability of excitatory neurons, 
could lead to the aberrant firing of excitatory neurons that underlies seizures.  The only 
proposed effect of the R853Q mutation that represents an anomalous channel function 
and, thus, explains how it may cause neuronal hyperexcitability, is the creation of a 
gating pore that conducts cationic current.  Neuronal resting membrane potential is 
typically around -70 mV, a membrane potential at which the gating pore in R853Q 
mutant channels is conducting, according to my results.  The inward cationic current, 
though small, flows through the channel when it is in its resting conformation and, 
therefore, it may chronically depolarize the affected neurons, making them 
hyperexcitable.  Multiple studies have shown that mutations of the highly conserved 
voltage-sensing residues in the second domain of Nav channels result in gating pore 
currents (Sokolov et al., 2005, 2007, 2008, 2010; Struyk & Cannon, 2007).  Patch clamp 
data and molecular dynamic simulations have shown that mutation of the second 
voltage-sensing arginine residue in the bacterial channel, which is homologous to the 
hNav1.2 residue R853, creates a distinct gating pore that is open in the resting state 
channel conformation (Gamal El-Din et al., 2014; Jiang et al., 2018).  In rat Nav1.2, the 
R853Q mutation, when paired with the R850Q mutation, produced an inward gating 
pore current in Xenopus oocytes, but the R853Q mutation alone did not produce an 
observable gating pore current that was significantly different from that of the wild-type 
rat channel (Sokolov et al., 2005).  This may indicate a species difference in 
susceptibility.  The R853Q mutation in hNav1.2 did not produce an observable gating 
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pore current in CHO cells (Berecki et al., 2018); however, this is likely due to the low 
current amplitude and density of R853Q channels in CHO cells.  We obtained robust 
expression of hNav1.2 channels in Xenopus oocytes and observed substantial gating 
pore currents with the hNav1.2 R853Q construct.  A linear correlation between the 
gating pore current amplitude and the gating charge has been observed in gating pore 
currents caused by Nav1.4 disease mutations (Struyk & Cannon, 2007; Mi et al., 2014), 
and we observed a similar correlation in the gating pore current caused by the R853Q 
mutation in Nav1.2 (Fig. 13A).  This provides validation that the current we observed 
was actually gating pore current.  The slope of this correlation observed in our 
experiments is -118.0 ± 8.8 nA/nC (n = 11).  By comparison, for the gating pore current 
observed with Nav1.4 in hypokalemic periodic paralysis mutants, the slopes range from 
50-150 nA/nC (Struyk & Cannon, 2007; Mi et al., 2014).  This indicates that the severity 
of the gating pore leak induced by R853Q in hNav1.2 is comparable to those observed 
with Nav1.4 disease mutations, and, therefore, that the gating pore current observed in 
our experiments with the R853Q mutation may be involved in the pathogenesis of 
epilepsy. 
Inward gating pore currents resulting from the mutation of one of the first two 
arginines in DIIS4 (in hNav1.2, R850 or R853) are predicted to destabilize and even 
chronically depolarize the membrane potential of affected neurons.  Gating pore 
currents may also disrupt intracellular ion homeostasis, allowing excess sodium ions and 
possibly even protons to leak into affected neurons through the gating pore (Struyk & 
Cannon, 2007; Sokolov et al., 2007).  Though the generation of gating pore current adds 
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an aberrant function to the hNav1.2 channel, the impact of this anomalous current may 
depend on the cell background.  A depolarizing influence, such as excess sodium entry 
into the cell, could increase the activity of some neurons by bringing the membrane 
potential closer to the action potential firing threshold, while paradoxically decreasing 
excitability in others if the depolarization of the membrane potential reduces sodium 
channel availability due to the accumulation of inactivated channels.  The other effects 
of the R853Q mutation confer a moderate loss of function on hNav1.2, which is 
predicted to contribute to decreased neuronal excitability.  This prediction was tested in 
2018 using a dynamic action potential clamp model.  This approach fuses voltage clamp 
of CHO cells transiently expressing Nav1.2 channels with a computer model of a typical 
cortical neuron axon initial segment, and it was used to predict that the R853Q mutation 
would decrease action potential firing activity and thus reduce overall neuronal 
excitability (Berecki et al., 2018).  However, the dynamic clamp model did not consider 
the possibility that gating pore currents may be induced by the R853Q mutation, and 
that these currents could alter neuronal activity directly, by reducing the action 
potential threshold, or indirectly, by chronically impacting ion homeostasis and energy 
metabolism in neurons.  Such alterations could cause variable and/or chronic changes in 
neuronal properties, and these changes may not be readily apparent using dynamic 
clamp or traditional electrophysiological analyses in heterologous expression systems. 
Moreover, seizures in patients with R853Q are refractory to AEDs that block the 
conventional sodium-conducting pore, consistent with a pathophysiological mechanism 
based on the gating pore current. 
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Though only one epilepsy patient with the R853Q mutation has been reported to 
have been diagnosed with autism (Butler et al., 2017), most patients that have been 
reported to have the same mutation reportedly suffered severe intellectual disability 
and/or developmental delays (Allen et al., 2013; Nakamura et al., 2013; Samanta and 
Ramakrishnaiah, 2015; Kobayashi et al., 2016; Li et al., 2016; Butler et al., 2017; Wolff et 
al., 2017; Lindy et al., 2018).  Since SCN2A mutations that appear to have exclusively 
loss-of-function effects are typically associated with autism, which is also a 
developmental disorder, the association of the R853Q mutation with predominately 
loss-of-function effects on channel function supports (and may explain) its association 
with phenotypes of severe developmental and intellectual disorders.  Since the overall 
effect of the R853Q mutation on neuronal excitability is unclear, its mechanistic role in 
epileptogenesis is undetermined.  If the mutation causes neuronal hyperexcitability, it 
could be reasoned that the gating pore current confers an overall gain-of-function effect 
on the channel via inducing gating pore current.  If it decreases neuronal 
hyperexcitability, another explanation for the seizure phenotype, such as compensatory 
upregulation of Nav1.6 in affected neurons that leads to neuronal hyperexcitability, 
must be considered.  
Though the mechanism by which the R853Q mutation causes the observed 
clinical phenotype is unclear, its high incidence in otherwise idiopathic epilepsy cases 
and the fact that mutations in the homologous residue in three other Nav isoforms 
(Nav1.1, 1.4, & 1.5) have been shown to be associated with disorders of excitability 
make it clear that it is a pathogenic mutation.  In addition to R853Q, ten other 
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neutralizing mutations of seven different voltage-sensing residues in Nav1.2 have been 
implicated in over 30 cases of epilepsy.  Three mutations in domains I and III of hNav1.2 
have been studied in vitro (R223Q, R1312T, & R1319Q), though none of these studies 
included analysis of gating pore currents.  Of these three, one (R1312T, in DIII) also 
exhibits a loss-of-function hyperpolarizing shift in fast inactivation, compared to wild-
type, but R1312T also exhibited multiple gain-of-function effects that were not seen in 
my experiments with the R853Q mutant (Lossin et al., 2012).  The other two (R223Q, 
R1319Q) were shown to have the opposite effect, exhibiting a depolarizing shift in the 
voltage dependence of fast inactivation (Scalmani et al., 2006; Misra et al., 2008).  The 
R1319Q mutation, like R853Q, has been shown to reduce the current density of Nav1.2; 
and the R1319Q mutation was also shown to reduce the surface expression of the 
channel (Misra et al., 2008), which, based on the data from this dissertation work, is also 
likely one effect of the R853Q mutation.  Clinically, the R853Q phenotype most 
resembles that of R1312T, causing severe seizures that are often refractory to 
antiepileptic medications, having a late onset (typically >6 mos.), and being 
accompanied by severe intellectual disability (Wolff et al., 2017; Kobayashi et al., 2016; 
Allen et al., 2013; Nakamura et al., 2013; Samanta and Ramakrishnaiah, 2015; Shi et al., 
2009). 
Only one other voltage-sensing residue in domain II of Nav1.2, R856, has been 
reported to have mutations implicated in epilepsy (Howell et al., 2015; Moller et al., 
2016; Wolff et al., 2017).  The R856L mutation has been identified in one patient who 
was diagnosed with epilepsy of infancy with migrating focal seizures (Howell et al., 
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2015), and the R856Q mutation was identified in two patients diagnosed with Ohtahara 
Syndrome (Moller et al., 2016; Wolff et al., 2017).  Neither mutation has been studied in 
the laboratory.  In contrast to patients with the R853Q mutation, the seizure onsets for 
R856L and R856Q patients was reported to be early (1-2 days) in two of the cases, 
representing both mutations (Howell et al., 2015; Wolff et al., 2017).  At least one child 
with the R856Q mutation was refractory to antiepileptic medicines and died at the age 
of 3 months (Moller et al., 2016; Wolff et al., 2017).  Since R853Q and R856Q are 
mutations of adjacent voltage-sensing residues in the functional Nav1.2 protein, the 
proximity of these two residues and the severe, refractory epileptic phenotypes caused 
by both suggests that these mutations may have similar effects on the structure, and 
thus also the function of the channel.  I predict that several, if not all, of these other S4 
mutations in hNav1.2 may also induce gating pore currents. 
 
R1882Q Mutation Effects on hNav1.2 Function and Predicted Effects on Neuronal 
Excitability 
Four different mutations of the R1882 residue in Nav1.2 have been reported as 
being putatively pathogenic in epilepsy cases (R1882L, R1882P, R1882G, & R1882Q) 
(Baasch et al., 2014; Schwarz et al., 2016; Howell et al., 2015; Trump et al., 2016; Carvill 
et al., 2013; Parrini et al., 2017; Wolff et al., 2017).  The biophysical effects of the 
R1882L and R1882P mutations have not been studied.  The R1882G mutation, which, 
like R1882Q, neutralizes the positive residue, has been shown to cause gain-of-function 
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effects on Nav1.2 channels in tsA201 cells, though the mutational effects on resurgent 
currents was not investigated (Schwarz et al., 2016). 
The 2018 study utilizing CHO cells revealed that the R1882Q mutation causes a 
depolarizing shift in the voltage dependence of fast inactivation, enhances persistent 
currents, and slows fast inactivation, compared to the wild-type channel (Berecki et. al).  
The results of the present study corroborate those findings.  Additionally, I show that 
the R1882Q mutation substantially enhances resurgent currents in HEK cells, whereas 
the CHO cell study did not address the possibility of changes in resurgent current due to 
this mutation.  In CHO cells the R1882Q mutation was also reported to increase peak 
current density and hyperpolarize the voltage dependence of activation (Berecki et al., 
2018), but I did not observe those effects in my experiments.  All of the observed 
changes enhance Nav1.2 channel function, which is predicted to increase neuronal 
excitability.  The dynamic action potential clamp experiments predicted that the 
R1882Q mutation would chronically depolarize neurons and increase their action 
potential firing activity (Berecki et al., 2018).  Importantly, this model system did not 
incorporate resurgent current mechanisms, which are predicted to further enhance the 
pro-excitatory impact of the R1882Q mutation.   
Resurgent currents have been identified as drivers of both repetitive action 
potential activity and spontaneous action potential generation (Raman and Bean, 1997; 
Bant and Raman, 2010; Khaliq et al., 2003; Barbosa et al., 2015; Xiao et al., 2019).  
Resurgent currents are also enhanced by pro-excitatory disease mutations in other 
voltage-gated sodium channel isoforms which are associated with pain, myotonia 
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congenital, long-QT syndrome, and SCN8A epilepsies (Jarecki et al., 2010; Patel et al., 
2016; Xiao et al., 2019).  Although ours is the first study to investigate the impact of 
SCN2A mutations on resurgent currents, recordings from DRG neurons demonstrated 
that Nav1.2 channels can produce resurgent currents in a neuronal background (Rush et 
al., 2005).  Altogether, this strongly suggests that the enhancement of resurgent 
currents by the R1882Q mutation is part of its pathogenic mechanism. 
The primary effect of the SCN2A R1882Q mutation is impairment of inactivation, 
which contributes to both increased persistent and resurgent currents (Grieco and 
Raman, 2004; Theile et al., 2011).  It has been shown that the C terminal domain of 
Nav1.2 (Mantegazza et al., 2001; Nguyen and Goldin, 2010; Lee and Goldin, 2008), as 
well as Nav1.3 (Nguyen and Goldin 2010), Nav1.5 (Cormier et al., 2002; Glaaser et al., 
2006), Nav1.6 (Lee and Goldin, 2008; Wagnon et al., 2016), and Nav1.8 (1.5 & 1.8; 
Motoike et al., 2004; Choi et al., 2004), is involved in modulating fast inactivation.  In a 
study utilizing ND7/23 cells, it was shown that the R1872Q mutation in mouse Nav1.6, 
which is homologous to the hNav1.2 R1882Q mutation, slows inactivation (as evidenced 
by increased inactivation time constants), hyperpolarizes the voltage dependence of 
activation, and depolarizes the voltage dependence of inactivation, compared to wild-
type (Wagnon et al., 2016).  Since Nav1.2 and Nav1.6 share a high degree of homology 
in structure and function (amino acid sequences have 75% identity, 85% similarity) 
homologous mutations in the two isoforms are predicted to have similar functional 
results.  My results demonstrate that, like the Nav1.6 R1872Q mutation, the R1882Q 
mutation increased inactivation time constants, indicating a slowing of fast inactivation, 
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and depolarized the voltage dependence of inactivation.  In my experiments, the 
R1882Q mutation also increased persistent currents at physiologically-relevant 
membrane potentials (amplitude increased significantly from -50 to -20 mV, % of 
transient current increased significantly from -45 to -25 mV).  This effect was seen when 
R1872 in Nav1.6 was mutated to leucine (L), but not when it was mutated to glutamine 
(Q) or tryptophan (W).  Additionally, the hNav1.2 R1882Q mutation enhanced resurgent 
currents, which were not investigated in the study of the mouse Nav1.6 R1872Q 
mutation.  There is substantial evidence suggesting that the C-terminal domain of 
voltage-gated sodium channels can modulate fast inactivation and persistent currents 
by interacting with the domain III/IV linker that contains the inactivation particle 
(Clairfeuille et al., 2019; Wagnon et al., 2016; Nguyen and Goldin, 2010; Lee and Goldin, 
2008; Motoike et al., 2004; Mantegazza et al., 2001).   The neutralizing R1882Q 
mutation may directly or indirectly alter this interaction, thus impairing inactivation and 
enhancing persistent currents.   
 
Effects of the Navβ4 Peptide and cDNA Expression Modality on Measured Parameters 
Since the original experimental setup included a WT group that was subjected to 
all the same conditions as the mutant groups, I am very confident in these results.  
However, in order to investigate whether the mutational effects I observed in the 
transiently transfected HEK cells were genuine and not due to the presence of the 
Navβ4 peptide or the cDNA expression modality, I repeated the experiments comparing 
WT, R853Q, and R1882Q mutations in three conditions:  transiently transfected cells in 
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the absence of the Navβ4 peptide, cell lines stably expressing hNav1.2 in the absence of 
the peptide, and cell lines stably expressing hNav1.2 in the presence of the peptide (WT 
vs. R1882Q only in this last experiment); and I compared the observed mutational 
effects across the four experimental conditions, which are summarized in Tables 4-5.  
Unfortunately, the four sets of experiments (transiently transfected cells with the 
peptide, transiently transfected cells without the peptide, cell lines stably expressing 
hNav1.2 with the peptide, and cell lines stably expressing hNav1.2 without the peptide) 
were performed in different time periods, so the four experimental datasets are non-
contemporaneous.  This caveat needs to be considered when comparing the results 
from the various experimental paradigms.  
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Transient Transfections without the Navβ4 Peptide 
In both the presence and absence of the Navβ4 peptide, the R853Q mutation 
produced a significant decrease in the average maximum peak transient current 
amplitude, compared to that of the WT channel.  Though the average estimated 
activation midpoint was slightly depolarized by the mutation in the absence of the 
peptide, no significant change was observed in this parameter in either condition, and 
the slight depolarizing shift is consistent with the effects of the full-length Navβ4 
subunit (Aman et al., 2009).  The average maximum inactivation midpoint was 
depolarized in both conditions, though only significantly in the presence of the peptide.  
While both the maximum peak persistent current amplitude and the maximum peak 
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persistent current expressed as percent of transient current were decreased in the 
presence of the peptide, the persistent current expressed as a percentage was non-
significantly increased by the R853Q mutation in the absence of the peptide.  The only 
significant change seen in the persistent current measurements between WT and R853Q 
mutant channels was a significant decrease in the average maximum persistent current 
amplitude in the presence of the peptide.  Thus, the mutation seems to decrease 
persistent currents in the presence of the peptide but have no effect on them in the 
absence thereof, in HEK cells transiently expressing hNav1.2 channels.  This discrepancy 
and the differences in significance seen in the effects of the R853Q mutation on 
maximum peak transient current density and average estimated midpoint of 
inactivation are likely due to the differences in sample sizes for the two conditions.  The 
sample sizes were much larger in the presence of the Navβ4 peptide (n = 41 WT, 16 
R853Q) than in its absence (n = 18 WT, 9 R853Q).  If the latter experiment had larger 
sample sizes, I would have expected the significances of the observed mutational effects 
to more closely resemble those in the former experiment.  I am more confident in the 
results of the former experiment than the results of the latter; and the mutational 
effects observed in the absence of the peptide echo those observed in its presence.  
Given this analysis of the R853Q mutation in both the presence and absence of Navβ4 
peptide, I am confident that the R853Q mutation decreases transient current, has no 
significant effect on activation, and hyperpolarizes the voltage dependence of 
inactivation in HEK cells transiently expressing the hNav1.2 channel.   
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The effects of the R1882Q mutation observed in the absence of the Navβ4 
peptide were very similar to the effects observed in its presence.  There was no 
significant change in the average maximum peak transient current amplitude or density 
in either condition, nor was there any change in the voltage dependence of activation.  
In both conditions, the voltage dependence of inactivation was significantly depolarized 
and the persistent current expressed as a percentage of transient current was 
significantly increased.  The maximum peak persistent current amplitude was increased 
in both conditions, though the increase was only significant in the presence of the 
Navβ4 peptide.  As stated above, the sample sizes were much larger in the presence of 
the Navβ4 peptide (n = 41 WT, 27 R1882Q) than in its absence (n = 18 WT, 6 R1882Q).  If 
the latter experiment had larger sample sizes, I would have expected the increase in the 
maximum peak persistent current amplitude in the absence of the peptide to be 
significant, compared to the corresponding WT control group. Given this analysis of the 
R1882Q mutation in both the presence and absence of the Navβ4 peptide, I am 
confident that the R1882Q mutation has no significant effect on transient current or the 
voltage dependence of activation, significantly depolarizes the voltage dependence of 
inactivation, and increases persistent currents in HEK cells transiently expressing the 
hNav1.2 channel. 
Considering my analyses of both the R853Q and R1882Q mutations in both the 
presence and absence of the Navβ4 peptide, I do not believe that the Navβ4 peptide 
had any significant effects on any of the biophysical effects observed in HEK cells 
transiently expressing hNav1.2 cDNA.  However, when the data from the WT groups in 
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the presence and absence of the peptide are compared (see Table 6), the peptide seems 
to produce hyperpolarizing shifts in the voltage dependencies of activation (~6.5 mV 
shift) and inactivation (~8 mV shift).  This suggests that, in recordings of HEK cells 
transiently expressing hNav1.2 cDNA, the Navβ4 peptide may produce hyperpolarizing 
shifts of similar magnitude in the voltage dependencies of activation and inactivation.  
This, however, did not impact the overall results, since each experiment had its own WT 
control group, to which the mutant groups in each experiment were compared.  
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Transient Transfections vs. Cell Lines Stably Expressing hNav1.2 
 In my analyses of the R853Q and R1882Q mutations in HEK cells stably 
expressing hNav1.2 cDNA, I found very few discrepancies in the observed mutational 
effects, compared to the effects I observed in transiently transfected cells. 
 Since the R853Q mutation was not studied in the presence of the Navβ4 peptide 
in the cell line stably expressing the mutant channel, the only comparison of results 
between transiently and stably expressing cells that can be made for this mutation are 
the results of the experiments in the absence of the peptide.  For the most part, the 
mutational effects seen in these two experiments were very similar.  Though each 
observed effect, which included decreased transient currents, depolarization of the 
voltage dependence of inactivation, and a decrease in the maximum peak persistent 
current amplitude, was only significant in one of the two datasets, the corresponding 
non-significant changes were in the same directions as the significant ones.  No 
significant change in the voltage dependence of activation or in the maximum peak 
persistent current expressed as a percentage of peak transient current was seen in cell 
lines stably expressing hNav1.2 or transiently transfected cells.  Therefore, the 
magnitude of the reduction in persistent currents by the R853Q mutation depends on 
the experimental conditions.  Several of the effects of the R853Q mutation on hNav1.2 
in HEK cells were consistent, at least in direction, across experimental conditions, which 
strengthened my confidence that they were truly functional effects of the mutation.   
These effects include a hyperpolarizing shift in the voltage dependence of inactivation, 
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decreases in peak transient and persistent currents, and no effect on the voltage 
dependence of activation. 
In the absence of the Navβ4 peptide, the R1882Q mutation caused very similar 
effects in transiently transfected cells and cell lines stably expressing hNav1.2.  In both 
groups, there were non-significant increases in peak transient currents, no change in the 
voltage dependence of activation, a significant depolarizing shift in the voltage 
dependence of inactivation, and a significant increase in the maximum peak persistent 
current expressed as a percentage of peak transient current.  The maximum peak 
persistent current amplitude was increased in both groups, though the increase was 
only significant in the results from the cell lines stably expressing the channels. 
 In the presence of the Navβ4 peptide, the R1882Q mutation caused very similar 
effects in transiently transfected cells and cell lines stably expressing hNav1.2; and the 
effects seen in these two experiments were very similar to the two experiments that did 
not utilize the peptide.  In all four experiments examining the R1882Q mutation, 
compared to the respective WT control groups, there was no change in the voltage 
dependence of activation, a significant depolarizing shift in the voltage dependence of 
inactivation, and a significant increase in the maximum persistent current expressed as a 
percentage of peak transient current.  The R1882Q mutation increased the maximum 
peak persistent current amplitude in all four experiments, of which three reached 
statistical significance.  The maximum peak transient current amplitudes and densities 
were not significantly altered by the R1882Q mutation in any of the experiments, 
though these parameters were slightly increased, compared to WT, in the two 
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experiments that did not utilize the Navβ4 peptide.  Since there was a large degree of 
consistency in the functional effects of the R1882Q mutation on hNav1.2 in HEK cells 
across all four experimental conditions, I am confident that this mutation depolarizes 
the voltage dependence of inactivation, enhances peak persistent currents, and does 
not alter peak transient currents or the voltage dependence of activation. 
The cDNA expression modality did seem to influence the effects of the R1882Q 
mutation on resurgent current in HEK cells.  In the presence of the Navβ4 peptide, 
compared to the respective WT control groups, the R1882Q mutation increased 
resurgent currents in the transiently transfected cells, but not in the cell lines stably 
expressing hNav1.2.  In fact, the average maximum peak resurgent current amplitude 
and the average maximum resurgent current expressed as percentage of transient 
current were slightly lower in the R1882Q group than in the WT group, in the 
experiment utilizing cell lines stably expressing hNav1.2.   This discrepancy in the effect 
on resurgent currents in transiently transfected cells versus cell lines stably expressing 
hNav1.2 suggests that the Nav1.2 channels are differentially modulated in transient and 
cell lines stably expressing hNav1.2.  For example, the cell lines stably expressing 
hNav1.2 may compensate for the initial increase in resurgent current by altering channel 
modifications such as phosphorylation levels.  An alteration in channel modification may 
speed or stabilize inactivation, or it might decrease trafficking and membrane 
expression levels of the channel.  An alteration of trafficking and membrane expression 
seems unlikely, since the transient peak current density is not altered by the cDNA 
expression modality.  However, a compensatory enhancement of inactivation may 
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develop over a matter of days or weeks in cells stably expressing R1882Q mutant 
channels. 
Our analyses of both the R853Q and R1882Q mutations in both transiently 
transfected cells and cell lines stably expressing the channels suggest that the modality 
of cDNA expression in HEK cells may significantly alter the measurements of peak 
persistent and resurgent currents, but that it does not affect the measurements of peak 
transient currents, the voltage dependence of activation, or the voltage dependence of 
inactivation. 
No consistent differences were observed when the data from the WT groups in 
the cell lines stably expressing hNav1.2 were compared to that of the WT groups in 
transiently transfected cells, (see Table 6).  When the data from cells stably expressing 
the WT channel were compared to that of the cells transiently expressing the WT 
channel in the presence of the Navβ4 peptide, I observed increases in the average 
maximum peak transient current amplitude and density, as well as in the average 
maximum peak persistent and resurgent current amplitudes.  However, the average 
maximum peak persistent and resurgent currents expressed as percentages of 
maximum peak transient current were not significantly different between these two WT 
groups.  This can be attributed to the fact that the average maximum peak transient, 
persistent, and resurgent currents were all augmented to similar degrees in the cell line 
stably expressing WT hNav1.2 channels, compared to the transiently transfected cells.  
While the voltage dependence of activation was distinctly hyperpolarized in the cell line 
stably expressing the channels, compared to the transiently transfected cells, the 
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voltage dependence of inactivation was unaltered.  When the data from cells stably 
expressing the WT channel was compared to that of the cells transiently expressing the 
WT channel in the absence of the Navβ4 peptide, the only difference observed was a 
slight hyperpolarization of the voltage dependence of activation in the cells stably 
expressing WT channels, compared to transiently transfected cells.  The 
hyperpolarization of the voltage dependence of activation that was seen in the cells 
stably expressing WT channels in the presence of the peptide and, to a lesser degree, in 
its absence suggests that the voltage dependence of HEK cells stably expressing hNav1.2 
cDNA may be hyperpolarized compared to transiently transfected cells.  This 
hyperpolarization decreases channel availability and may represent an adaptation of 
HEK cells to the new extraneous channels.    This, however, did not impact the overall 
results, since each experiment had its own WT control group, to which the mutant 
groups in each experiment were compared. 
 
Overall Effects of the L835F, R853Q, and R1882Q Epilepsy Mutations on hNav1.2 
Channel Function 
 The overall effects of the three mutations in my experiments with HEK cells are 
noted in bold in Table 7.  Cross-experimental comparisons revealed that the effects of 
the R853Q and R1882Q mutations were fairly consistent across experimental 
conditions.   Several effects of each mutation were consistent across my experiments, 
including highly consistent effects on the transient current measurements, voltage 
dependence of activation, and persistent current measurements, as well as a consistent 
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lack of effect on the voltage dependence of activation.  Therefore, I am very confident in 
the results reported here for the L835F, R853Q, and R1882Q mutations.  
 
 
Pharmacology 
The primary goal of this study was to characterize the functional effects of three 
missense mutations on the hNav1.2 channel, in order to develop a better understanding 
of the mechanisms by which ion channel mutations lead to seizure disorders.  The 
various profiles of biophysical functional changes caused by the epileptogenic SCN2A 
mutations that have been studied in vitro suggests that distinct missense mutations in 
hNav1.2 have different biophysical mechanisms of seizure generation.  For example, 
R853Q and R1882Q both lead to severe epilepsy, though with distinct clinical 
phenotypes (Allen et al., 2013; Nakamura et al., 2013; Samanta and Ramakrishnaiah, 
2015; Kobayashi et al., 2016; Carvill et al., 2013; Howell et al., 2015; Trump et al., 2016; 
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Wolff et al., 2017); and, in this study, these mutations have opposite effects on hNav1.2 
persistent current, resurgent current, and voltage dependence of inactivation.  Given 
that distinct missense mutations in the same ion channel generate seizures by unique 
molecular mechanisms, individual mutations may require targeted 
pharmacotherapeutic strategies in order to normalize the channel activity and prevent 
epileptogenesis (seizure generation).  For example, epileptic patients with a mutation 
that increases persistent current as the primary pathological effect (e.g. A263V, Parrini 
et al., 2017) would benefit from a pharmacological compound that selectively or 
preferentially inhibits persistent current; while the same compound would likely be 
ineffective in patients with mutations generating seizures through a loss of channel 
expression (e.g. R102X, Kamiya et al., 2004).  An ideal pharmacotherapeutic strategy for 
any epileptic patient with a pathogenic SCN2A mutation may involve selectively, or at 
least preferentially, targeting the specific pathological biophysical effects of each 
mutation, which may include the enhancement of aberrant currents such as persistent 
and resurgent currents, or the generation of a gating pore.  Such a strategy would 
maintain or restore healthy channel conductance and gating, as is seen in wild-type 
hNav1.2 channels, so as not to produce excessive sedation or other adverse effects in 
patients.  My data (work published in Mason and Cummins, 2020, available at 
https://www.mdpi.com/1422-0067/21/7/2454) suggests that CBD and GS967 
preferentially inhibit, respectively, resurgent and persistent current over transient 
current; and therefore that these compounds may be more effective than current AEDs 
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with less severe side effects, especially in patients with SCN2A mutations that enhance 
resurgent and/or persistent currents.   
 Though CBD reduced transient current density in this study, CBD inhibited the 
transient current density to a lesser degree than the resurgent current.  The inhibition of 
resurgent current density by CBD was significantly different from that of the vehicle and 
untreated control groups over a wider range of voltages than its inhibition of transient 
current density.  The selectivity of CBD for resurgent current is also suggested by the 
significant inhibition of maximum peak resurgent current density and the lack of 
significant inhibition of maximum peak transient current density.  The vehicle for CBD, 
methanol, mildly reduced hNav1.2 resurgent current densities at negative voltages, but 
the inhibitory effect of CBD was significant even compared to the methanol effect.  
There was also a trend toward inhibition of persistent current by both methanol and 
CBD, though this effect was not significant according to the limited analysis that I 
performed.  In this study, CBD produced a significant depolarizing shift in the voltage 
dependence of activation (see fig. 19A), which contributed to the inhibition of current 
densities by limiting channel availability.  As seen with WT hNav1.6, 1 μM CBD 
significantly reduced the maximum resurgent current (measured both as resurgent 
current density and as a percentage of transient current amplitude; latter data not 
shown) in HEK cells stably expressing hNav1.2, while not significantly reducing the 
maximum peak transient current density.  The same study that demonstrated the ability 
of CBD to block resurgent currents over transient currents in WT hNav1.6 also 
demonstrated its ability to preferentially block aberrant resurgent and persistent 
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currents generated by epileptogenic SCN8A (hNav1.6) mutations (Patel et al., 2016).  
Given the similarities in structure and function between Nav1.2 and Nav1.6, their 
predominant expression in excitatory (vs. inhibitory) neurons, and the similarities 
between their responses to CBD, I predict that CBD will demonstrate preferential 
inhibition of aberrant resurgent and persistent currents caused by epileptogenic 
hNav1.2 (SCN2A) mutations.  Given the ability of CBD to preferentially inhibit resurgent 
currents over transient currents in hNav1.2 and hNav1.6 and its efficacy even in 
refractory cases of epilepsy, I predict that this compound will prove to be a more 
effective AED than standard treatments such as phenytoin for patients with Nav 
mutation-associated epilepsies. 
GS967 reduced transient and resurgent currents to similar degrees.  The 
inhibition of resurgent current density by GS967 was significantly different from vehicle 
over a narrower range of voltages than its inhibition of transient current density (see fig. 
18B, D).  Neither the maximum peak transient current density nor the maximum peak 
resurgent current density were significantly reduced by this compound (see fig. 18A, C).  
The significant inhibition of transient and resurgent current densities in the current 
density-voltage relationships can be attributed to the depolarizing shift in the voltage 
dependence of activation elicited by DMSO and the hyperpolarizing shift in the voltage 
dependence of inactivation elicited by GS967, which both reduce channel availability.  
The hyperpolarizing shift in inactivation also suggests that GS967 could be a state-
dependent Nav inhibitor, like phenytoin.  My limited analysis of the effect of GS967 on 
persistent current suggested that GS967 may inhibit persistent current to a larger 
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degree than transient current in HEK cells stably expressing WT hNav1.2 (see fig. 18E).  
The effects of 1 μM GS967 on WT hNav1.2 seen in this study are congruent with 
previous reports that GS967 preferentially inhibits persistent current over transient 
current and hyperpolarizes the voltage dependence of inactivation in pyramidal neurons 
from the brains of mouse models of SCN8A epilepsy and in ND7/23 cells expressing the 
corresponding mutation (Baker et al., 2018; Bunton-Stasyshyn et al., 2019; Wengert et 
al., 2019).  Also, as in this study, WT Nav1.6 resurgent current was not significantly 
inhibited by GS967 in pyramidal subiculum neurons from one of these mouse models, 
though the compound did inhibit resurgent and persistent currents that were aberrantly 
enhanced by the epilepsy mutation (Wengert et al., 2019).  GS967 has been shown to 
prolong the survival of mice expressing two different SCN8A epilepsy mutations (Baker 
et al., 2018; Bunton-Stasyshyn et al., 2019) and protect against both spontaneous and 
evoked seizures in genetic models of SCN1A, SCN2A, and SCN8A epilepsies (Anderson et 
al., 2014, 2017; Baker et al., 2018).  Further studies need to be performed in order to 
confirm the ability of GS967 to preferentially block persistent over transient hNav1.2 
currents and investigate whether or not it preferentially blocks persistent and resurgent 
currents aberrantly enhanced by SCN2A epilepsy mutations; and no phase 2 clinical 
trials have been performed to evaluate its efficacy as an antiepileptic drug in humans.  
Given the ability of GS967 to preferentially inhibit persistent over transient and 
resurgent currents in WT Nav channels, its propensity to preferentially block aberrant 
persistent and resurgent currents associated with Nav epilepsy mutations, and its 
efficacy as an AED in preclinical models of epilepsy, I predict that this compound will 
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prove to be a more effective AED than standard treatments such as phenytoin for 
patients with Nav mutation-associated epilepsies.   
 As of early 2020, there have not been any reported studies examining the effects 
of AEDs on gating pore current, but the refractoriness of most reported R853Q epilepsy 
cases suggests that the conventional AEDs do not block the primary pathogenic effect(s) 
of the mutation.  My collaborators and I propose that the gating pore current created by 
the R853Q mutation is its primary pathogenic mechanism, and that this current must be 
selectively targeted in order to prevent seizures in patients with this mutation.  One 
pharmacotherapeutic strategy that could be pursued in order to selectively target gating 
pore current through a given domain is the development of a gating modifier molecule 
that interacts with the voltage sensor in that domain.  Gating modifiers alter the gating 
kinetics of ion channels, and most that have been shown to impact Nav channel function 
are toxins.  The crab spider toxin, Hm-3, has been reported to inhibit gating pore 
currents generated by a Nav1.4 disease mutation in the voltage sensor of domain I by 
interacting with the voltage sensor in that domain (Männikkö et al., 2018).  Hm-3 did 
not inhibit gating pore current caused by disease mutations in the voltage sensors in 
domains II or III, suggesting that it selectively targets the voltage sensor and gating pore 
in domain I.  It also strongly inhibited transient currents in WT channels, so it remains to 
be determined whether or not this toxin preferentially inhibits gating pore current over 
transient current in WT or mutant Nav1.4, or in any other Nav isoform (Männikkö et al., 
2018).  Hm-3 has been shown to inhibit transient current in most Nav channel isoforms, 
though it is selective, in this respect, for Nav1.4 and Nav1.5 over Nav1.1, Nav1.2, 
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Nav1.3, Nav1.6, and Nav1.8 (Berkut et al., 2015).  The authors of the 2018 study 
suggested that Hm-3 binds to the voltage sensor of domain I in Nav1.4 with a higher 
affinity when the channel is in the closed conformation, either directly occluding the 
gating pore or causing a shift in the local channel conformation that occludes the gating 
pore.  Toxins or other molecules that have similar mechanisms of action through 
interactions at other voltage sensing segments could be sought in order to inhibit gating 
pore currents generated by disease mutations in domains II-IV.  These molecules and 
Hm-3 could be used as templates for the development of drugs that selectively inhibit 
gating pore current through each domain without notably inhibiting the transient 
current.   One caveat of this method to consider is that, if a molecule interacts with the 
voltage sensor of the affected domain in such a way that shifts the sensor slightly so 
that the gating pore is occluded indirectly, this could bias the channel toward or away 
from activation.  This could result in an aberrant increase or decrease, respectively, in 
neuronal excitability, which could cause unintended CNS effects such as exacerbation of 
seizures or sedation.  Nevertheless, novel AEDs that selectively inhibit gating pore 
current over transient current could prove to be effective in preventing seizures in 
patients with refractory epilepsy caused by mutations that result in gating pore 
currents.  
 
Applications 
Our data demonstrated that neutralizing a voltage-sensing residue in hNav1.2 
(R853Q) creates a gating pore that does not exist in the WT channel.  This is the first 
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demonstration of this phenomenon as an effect of a disease mutation in a neuronal Nav 
channel.  Many of the over two dozen S4 charge neutralizing mutations in Nav1.1, 
Nav1.2, and Nav1.6 that have been identified in patients with epilepsy may also induce 
gating pore currents that contribute to the disease phenotype.  Due to their physical 
distinction from the central pore, where traditional sodium channel blockers have been 
shown to bind, gating pore currents are unlikely to be targeted by standard clinical 
therapies.  Thus, novel approaches, such as blocking the gating pore with a gating 
modifier molecule, may be needed to ameliorate the impact of the gating pore currents 
produced by some neuronal sodium channel disease mutations. 
Our data also demonstrated that enhancement of resurgent currents is an effect 
of at least one epileptogenic SCN2A mutation that is likely involved in the pathogenesis 
of the resulting epilepsy.  Therefore, as suggested with Nav1.6 epilepsy mutations (Patel 
et al., 2016), I believe that targeting resurgent Nav currents over transient Nav currents 
is a valuable strategy for the treatment of epilepsy.  The results of my study of CBD 
suggest that this compound targets resurgent current over transient current in hNav1.2, 
as it does in hNav1.6, (both of which are neuronal Nav channels predominantly 
expressed in excitatory/pyramidal neurons) and thus that this preferential inhibition 
contributes to its proven efficacy as an AED.   
Persistent currents are known to be enhanced by some epileptogenic SCN2A 
mutations, and that enhancement is believed to be involved in the pathogenesis of the 
resulting epilepsies.  The results of my study with GS967, along with previous studies, 
suggest that this compound preferentially inhibits persistent neuronal Nav currents over 
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transient neuronal Nav currents.  Therefore, as suggested in the context of Nav1.6 
epilepsies (Baker et al., 2018; Wengert et al., 2019), I believe that targeting persistent 
Nav currents over transient Nav currents is a valuable strategy for the treatment of 
epilepsy, and that GS967 will thus prove to be an efficacious AED in human patients. 
Ultimately, I expect that this research will contribute to a knowledge base and 
resources that will lead to more effective treatments for patients with epileptogenic 
SCN2A mutations.  The next step in that process will be screening conventional 
antiepileptic drugs and novel, putatively antiepileptic compounds in cells expressing 
mutant hNav1.2 channels, with the aim of discovering the compound that best 
normalizes the channel activity (to resemble that of wild-type) for each mutation.  The 
therapeutic value of such compounds could be confirmed in neurons expressing the 
mutant channels, and the correlation of patient-reported efficacy of conventional 
antiepileptic drugs with the effects of the same drugs on mutant channels in vitro could 
be studied.  If the correlation is strong, then the in vitro studies could provide 
suggestions of compounds that will likely be efficacious in patients with particular 
epileptogenic mutations.  
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V.  FUTURE DIRECTIONS 
In Vitro Studies 
 This study characterized the biophysical effects of three epileptogenic SCN2A 
mutations on hNav1.2 channels, but these channels were transiently expressed in 
HEK293 cells.  Though they are human cells with a full set of human DNA, HEK293 cells 
are not neurons.  Their endogenous expression of voltage-gated sodium and potassium 
channels, both of which are strongly endogenously expressed in neurons, is weak (He 
and Soderlund, 2010).   Primarily for this reason, HEK293 cells are not excitable and 
cannot conduct action potentials.  This weak endogenous voltage-gated ion channel 
expression makes HEK293 cells a great cell type in which to study the effects of various 
mutations and treatments on the function of an isolated voltage-gated sodium channel 
isoform.  However, this method does not consider the potential effects of cell type-
specific protein expression or membrane compositions on channel function.  Though 
HEK293 cells share some genetic characteristics of neuronal stem cells (Shaw et al., 
2002), the differences in proteome and protein expression levels may result in 
differences in the functionality of the voltage-gated sodium channels in HEK cells and 
neurons.  For example, neurons in many brain regions express FGF14b (Wang et al., 
2002), which has been shown to inhibit transient currents in Nav1.1, Nav1.2, Nav1.5, 
and Nav1.6 (Lou et al., 2005; Laezza et al., 2009) and to generate resurgent currents in 
cerebellar Purkinje neurons (Yan et al., 2014; White et al., 2019).  FGF14b is not known 
to be expressed in HEK293 cells, and thus, FGF14b may modulate transient and 
resurgent currents in neurons in ways that are absent in HEK293 cells expressing the 
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same Nav channel isoforms.  Additionally, the membrane compositions of HEK293 cells 
and neurons may differ substantially, so the Nav channels in the membranes of the two 
cell types likely differ in their molecular interactions with surrounding membrane 
components and in the resulting modulations that those interactions may have on Nav 
channel function.   
 Since HEK293 cells are not excitable, this method does not allow for the direct 
study of the effects of mutations or treatments on neuronal (or other cellular) 
excitability.  Therefore, further studies of these and other epileptogenic SCN2A 
mutations in neurons are needed in order to confirm that these mutations alter Nav 
channel function and excitability in neurons.  Voltage-clamp studies of SCN2A epilepsy 
mutations should include the analysis of mutational effects on all of the parameters 
included in this study, as well as on membrane trafficking in neurons.  Though some 
studies have revealed defects in membrane expression levels of Nav1.2 channels 
bearing epilepsy mutations in HEK cells, it is unclear whether or not these trafficking 
defects also occur in neurons endogenously expressing SCN2A epilepsy mutations.  
Membrane expression assays, such as immunocytochemistry, could reveal trafficking 
defects associated with particular mutations, which could contribute to the 
pathogenesis of the disease.   
 For neuronal studies, there are multiple potential experimental strategies.  The 
source and type of neurons, method of mutation expression, and culture setup of the 
neurons are all variables that could affect the experimental results. 
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The neurons could be derived from induced pluripotent stem cells (iPSCs), or 
they could be primary cultures from rodents or humans.  Human primary neurons could 
come from a collaborating neurologist or biobank and would likely be derived from 
resections of diseased brain tissues.  The mutation of interest could be introduced into 
the neurons via one of several different methods.  A point mutation conferring 
resistance to TTX could be introduced into the cDNA for the WT and mutant forms of 
the channel, and these channels could be transiently transfected into the neurons, so 
that TTX could be used in the bath solution to inhibit all endogenous TTX-sensitive (TTX-
S) Nav currents and limit the Nav currents to TTX-resistant (TTX-R) channels in the 
neurons.  All of the Nav channel isoforms expressed in the brain (Nav1.1, Nav1.2, 
Nav1.3, and Nav1.6) are TTX-S, so saturating brain neurons with TTX would limit voltage-
gated sodium currents to the exogenous TTX-R channels that are transfected in, which 
may result in decreased excitability of the neurons, if whole-cell currents and resulting 
depolarization fall short of the endogenous whole-cell currents and depolarization.  
Another approach could be to knock down endogenous Nav1.2 channel expression with 
shRNA and transiently transfect the channel bearing the epilepsy mutation, then 
studying the neurons in the absence of TTX.  For studies generating and/or utilizing 
genetic animal models of epilepsy, in which the animal heterozygously expresses the 
mutation of interest, wild-type littermates could be used as controls; and the WT or 
mutant channel of interest would be endogenously expressed in primary neurons.  If the 
study allows for the generation of induced pluripotent stem cells, fibroblasts from 
patients and unaffected siblings or other close relatives without the mutation could be 
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used to generate iPSCs that are then differentiated into model neurons.  If cells from 
epileptic patient(s) with the mutation of interest are not available, CRISPR-Cas9 could be 
utilized to induce the point mutation in healthy iPSCs, which could then be 
differentiated into model neurons.  Pluripotent stem cells induced from human 
fibroblasts have demonstrated great potential as research tools since around 2010, and 
multiple techniques have been described for the effective differentiation of these stem 
cells into fully functional neurons (Zhang et al. 2013, Mariani et al. 2012, Espuny-
Camacho et al. 2013).  The predictive value of drug screens utilizing hiPSC-derived 
neurons has not been strongly established as of early 2020, but it has been supported 
by demonstrating that hiPSC-derived motor neurons modeling ALS mimicked human 
patients’ failure to respond to two trial drug compounds. 
The neurons could be cultured at a low density, in order to study isolated cells, 
or at a high density, in order to study neurons in a network.  Studying isolated cells is 
informative regarding mutation and drug effects on individual neuronal excitability and 
activity, but this experimental approach fails to properly recapitulate the complexity of a 
neuron’s environment and activity in vivo.  Thus, studying neurons in a network can also 
provide valuable translational insights.  In the patients’ brains, the affected neurons are 
highly integrated into a neuronal network, likely receiving input from multiple 
presynaptic neurons and releasing neurotransmitters to influence multiple postsynaptic 
neurons.  This enables synchronous firing of many interconnected neurons, which is 
believed to cause the large-amplitude bursts of activity seen on EEGs of epileptic 
patients during seizures.  Additionally, since Nav1.2 is implicated in backpropagation, 
 121 
studying the effects of SCN2A mutations on neurons in a network allows for the 
investigation of the effects of the mutations on synaptic plasticity.    Microelectrode 
array (MEA) culture dishes, which have a grid of electrodes built in and exposed on the 
bottom, can be used to study the synchronous bursting activity of both dissociated 
neurons and intact brain slices (Dossi et al., 2014; Gullo et al., 2014; Tidball and Parent, 
2016).  This approach could be useful in confirming the pathogenicity of epilepsy-
associated Nav mutations, as well as for screening AEDs against specific epileptogenic 
Nav mutations.  Therefore, this could prove to be a valuable tool in the development of 
personalized medicine for epilepsy patients.  Cerebral organoids are showing promise as 
in vitro models of brain development and disorders, and these may constitute another 
highly translational model in which to study the pathogenesis, including the temporal 
development, of genetic epilepsies (see Antill-O’Brien, Bourke, and O’Connell, 2019 for 
review). 
Though the study of the effects of Nav epilepsy mutations in cultured neurons 
derived from patient iPSC cells holds high translational value, it may still fail to properly 
model the complexity of the human disease.  There are many neuronal subtypes in the 
brain, each expressing a slightly different milieu of genes, and it is unclear which of 
these subtypes express SCN2A.  Therefore, the cell-specific background of the affected 
neurons in the patients, such as which Nav α and β subunits they express or what 
genetic modifiers may be present, is unknown.  Also, neurons in culture may not 
respond to the mutations in the same ways, or to the same extent, as do the affected 
neurons in the patients’ brains.  For example, there could be compensation that occurs 
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in patients’ brains that relies on a gene that is expressed in the affected neuronal 
subtype but not in the cultured neuronal population.  However, as studies continue to 
characterize the neuronal subtypes in the human brain, scientists will be better able to 
recreate these neuronal subtypes, including the affected neurons, more accurately in 
culture. 
 The pharmacological experiments in this dissertation work included only single 
doses of two antiepileptic compounds, CBD and GS967, tested on HEK cells stably 
expressing WT hNav1.2 channels.  Additional studies of the effects of these drugs on 
transient, resurgent, and persistent currents in neurons could be performed in HEK cells 
or neurons to investigate whether they preferentially inhibit currents that are aberrantly 
enhanced by epilepsy mutations in neuronal Nav channels.  Dose-response studies could 
be performed to validate the selectivity of CBD and GS967 for, respectively, resurgent 
and persistent currents; these studies would be expected to reveal a greater potency of 
the drug for the inhibition of resurgent or persistent current than for the inhibition of 
transient current.  Further studies should be performed to examine the effects of a 
panel of AEDs and potentially antiepileptic compounds on both WT hNav1.2 channels 
and hNav1.2 channels expressing epilepsy-associated mutations, expressed in isolation 
or co-expressed with WT channels in HEK293 cells, in order to examine their abilities to 
block aberrant resurgent and persistent currents over transient current and restore 
functionality of mutant channels to resemble that of WT.  The compounds should also 
be studied in neurons to determine their effects on neuronal Nav currents and 
excitability, in both the presence and absence of epilepsy Nav mutations.  In both HEK 
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cell and neuron studies, the compounds should be tested at varying concentrations, in 
order to generate concentration-response curves.  These studies would aim to find one 
or more compounds that selectively block aberrant currents generated by epilepsy 
mutations while not notably blocking healthy WT currents, thus blocking aberrant 
hyperexcitability in affected neurons.  I expect that such compounds would 
demonstrate greater potency and efficacy than conventional AEDs, and that CBD and 
GS967/Prax330 will be the first drugs in this novel subclass of AEDs. 
 
In Vivo Studies 
Though in vitro studies seem to confirm the pathogenicity of many SCN2A 
epilepsy mutations, further studies are needed to show that these mutations actually 
cause epilepsy phenotype (e.g. spontaneous seizures) in vivo. 
Rodent models of epilepsy have been used to test the antiepileptic potential of 
novel drug compounds for over 70  years, but until the 21st century, these models 
typically required experimental induction of epilepsy (e.g. by electroshock or PTZ, status 
epilepticus (SE) induced by kainite or pilocarpine).  Early genetic rodent models of 
epilepsy resulted from random mutagenesis or spontaneous mutations, but the 
mutations were not necessarily in genes homologous to those implicated in human 
cases of epilepsy.  The responses of these early epilepsy model rodents to AEDs has 
generally been highly predictive of the human patient response, but these models only 
model the predominant phenotypes of epilepsy and not the etiology.  Though some of 
the induced epilepsy models reproduce the phenotype of refractory seizures, it is highly 
 124 
unlikely that the induction method produces the same biophysical effects and 
complexity as do the mutations that often underlie refractory seizures in the patients.  
In order to confidently identify antiepileptic compounds that will effectively and 
specifically block the pathogenic molecular mechanism of epilepsy mutations in human 
patients, animal models bearing the responsible mutation and corresponding epilepsy 
phenotype are needed.  These genetic models of epilepsy could be used to study the 
disease itself, investigate novel antiepileptic therapies, and screen compounds to tailor 
the pharmaceutical treatment to the molecular etiology of the patient’s epilepsy.  
Progress in the development of genetic rodent models of SCN2A epilepsy is slow and 
challenging, although the costs of advanced genetic approaches to the development of 
such models, such as CRISPR/Cas9 gene editing, are decreasing.  Dravet Syndrome, the 
predominant form of SCN1A epilepsy, can be modeled fairly simply by the knockdown or 
knockout of one allele of SCN1A, which mimics the loss of function in that gene and the 
resulting Nav1.1 protein due to the human patients’ mutations.  There are two mouse 
models of epilepsy that heterozygously express pathogenic human SCN8A mutations 
(Wagnon et al., 2015; Bunton-Stasyshyn et al., 2019), but so far there are no such 
rodent models bearing human SCN2A mutations.  The Q54 mouse line, which bears an 
SCN2A transgene with the GAL879-881QQQ mutation in the cytoplasmic S4-S5 linker of 
domain II, was established as an SCN2A model of epilepsy in 2001 (Kearney et al.), but 
this particular triplet of point mutations has not been reported in any human cases of 
epilepsy.  Efforts are ongoing to develop mice heterozygously expressing epilepsy-
associated SCN2A mutations.  One lab has reported producing a mouse strain 
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heterozygous for the R1882Q mutation, which display spontaneous seizures as early as 
postnatal day 1 and do not survive past postnatal day 30 without treatment (Petrou et 
al., 2018), but as of early 2020, these claims have not been substantiated by publication.  
Another lab claims to have produced a mouse strain heterozygous for the R853Q 
mutation, but this claim is also unsubstantiated and these animals do not display any 
spontaneous seizures or increased susceptibility to induced seizures, whereas the 
human patients heterozygous for this mutation experience severe spontaneous 
seizures.  The challenges in generating a mouse model bearing an epileptogenic SCN2A 
mutation and a corresponding phenotype of spontaneous seizures or increased 
susceptibility to seizures are not well understood, but they may include species 
differences in gene expression in the affected neurons, which could result in differences 
in Nav channel modulation. 
Another promising model organism for the study of epilepsy is the zebrafish 
(Danio rerio).  Though they are not as closely related to humans as mice and rats in 
terms of genetics or anatomy, they are vertebrates, and zebrafish expressing mutations 
in multiple genes implicated in human cases of epilepsy do show increased susceptibility 
to seizures compared to wild-type fish (Schoonheim et al., 2010; Zhang et al., 2015; 
Grone et al., 2016; Pena et al., 2017; Zabinyakov et al., 2017).  Their reproduction results 
in a large number of progeny that develop more quickly than their rodent counterparts, 
which makes the zebrafish favorable as a model organism in which to conduct high-
throughput drug screens.  Housing and care of the zebrafish is cost- and space-efficient, 
and there is no known risk of developing allergies to them from working with them in 
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the lab.  Since they develop independently in transparent eggs from the moment of 
fertilization, their entire development can be easily observed and studied, without 
requiring the sacrifice of any adults, as is required in the study of the prenatal rodent 
brain.  The larvae themselves are also mostly transparent until about 3 weeks post-
fertilization, which enables in vivo imaging and electrophysiology studies.  By about 3 
days post-fertilization, excitatory glutamatergic (Higashijima et. al. 2004), inhibitory 
GABAergic (Higashijima et. al. 2004, Mueller et. al. 2006), and monoaminergic (Kaslin 
and Panula 2001, McLean and Fetcho 2004) neurons are present in the brain, confirming 
at least a moderate degree of neuron subtype homology between zebrafish and 
humans.  
The zebrafish homologue of human Nav1.2 (SCN2A) is the Scn1lab gene.  It is 
also homologous to human Scn1a and Scn3a, and, like its human homologues, it is 
expressed predominantly in the central nervous system (Novak 2006).  In zebrafish, it 
can be found throughout the brain and hindbrain and in ventral regions of the spinal 
cord by 48 hours post-fertilization (Novak 2006).  The Scn1lab and SCN2A gene products 
are 79% identical. While this is a relatively high identity (Scn1lab and SCN1A are 76% 
identical), the pharmacology of Scn1lab and SCN2A sodium channels could differ in 
important aspects such as cell type distribution and AED binding affinities.  This could 
diminish the predictive accuracy/value of the zebrafish model, but parallel in vitro 
assays using human channel construct bearing the mutation of interest could be 
performed to confirm that the drug responses in those models correspond to the drug 
responses of the model fish.  Chemical mutagenesis and morpholino knockdown of 
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Scn1lab have been used to generate zebrafish models of Dravet Syndrome (Schoonheim 
et al., 2010; Zhang et al., 2015), which have been used to screen non-AED FDA-approved 
drugs for antiepileptic therapeutic potential and identify a few that may be efficacious in 
Dravet Syndrome patients (Griffin et al., 2018; Sourbron et al., 2019).  This suggests 
that, if zebrafish with gain-of-function Scn1lab mutations can be generated and shown 
to have an epileptic phenotype, they may be a useful platform in which to screen 
epilepsy drugs for efficacy.   
Efforts to create point mutations in zebrafish homologous to those found in 
genetic human epilepsies using CRISPR/Cas9 have yielded very low success rates thus 
far, and we were unable to generate zebrafish bearing point mutations in Scn1lab with 
that technique in my collaboration with the Marrs lab (IUPUI School of Science, Dept. of 
Biology).  We were, however, successful in generating a transgenic zebrafish that 
expressed the WT human SCN2A gene, under a zebrafish neuron-specific promoter 
(Satou et al., 2013), alongside both endogenous Scn1lab alleles.  The expression of an 
extraneous neuronal Nav gene has proven useful in a model of cardiac arrhythmia 
associated with a Nav1.5 mutation (Huttner et al., 2013).  Our transgenic zebrafish 
model is still in development as of early 2020, but we hope to use CRISPR/Cas9 to create 
epilepsy point mutations in the transgene and thus produce genetic zebrafish models of 
epilepsy that can be used to screen for antiepileptic compounds that may protect 
against seizures in patients with epilepsy caused by SCN2A channel mutations.  We 
expect that the phenotypic effects of epileptogenic mutations in the transgenic human 
Nav channel gene will include abnormal swimming behavior (e.g. alterations in average 
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swimming velocity, whirlpool-like swimming, or bursts of erratic activity) and bursts of 
abnormal electrophysiolgical activity in the brain.  We expect that the phenotypic 
effects will be either spontaneous in mutant fish and absent in WT fish or more easily 
evoked in mutant fish than WT fish.  If this transgene model of epilepsy is unsuccessful, 
we may return to the CRISPR-Cas9 mutagenesis strategy using an optimized protocol, 
such as the one published by Prykhozhij et al. in 2017.  Once the effects of the Nav1.2 
channel mutations in zebrafish have been characterized, these fish could be used to 
screen for antiepileptic pharmacological compounds that reduce or eliminate those 
effects. 
Since generating mutant zebrafish could be a much faster process than 
generating mutant mice, we hope to establish a high-throughput screening system in 
which we can screen potentially antiepileptic compounds using zebrafish modeling ion 
channelopathies that cause treatment-resistant epilepsies in humans.  Zebrafish 
screening assays would aim to identify compounds that inhibit the rapid swimming and 
convulsive behavior of the mutant zebrafish, and electrophysiological analyses would 
need to be performed to confirm that they also inhibit the epileptiform electrical 
discharges in the brain.  Such a compound would be further investigated, using other 
model systems, to further substantiate its potential therapeutic efficacy against clinical 
seizures caused by the particular mutation being studied.  We believe that this approach 
could be used to identify compounds that are effective in preventing seizures in patients 
with Nav1.2 mutation-driven epilepsy that is refractory to the conventional antiepileptic 
treatments.     
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VI.  SUMMARY AND CONCLUSIONS 
 Missense mutations in SCN2A and other genes are increasingly being identified 
as causative in otherwise idiopathic cases of epilepsy, many of which are refractory to 
traditional antiepileptic drugs (AEDs, e.g. phenytoin, carbamazepine, levetiracetam, 
etc.).  Our understanding of how these mutations alter the channel function and 
neuronal excitability is limited, so this study aimed to characterize the biophysical 
effects of three SCN2A mutations that are associated with refractory epilepsy and 
expand our understanding of the potential pathogenic biophysical effects of these 
mutations.  I also sought to investigate the abilities of two novel antiepileptic 
compounds, CBD and GS967, to preferentially inhibit persistent and/or resurgent 
currents over transient current.  The results of this dissertation work suggest that 
individual SCN2A epilepsy mutations alter hNav1.2 channel function differently, and that 
changes in resurgent current and the creation of a gating pore current should be 
considered as potential pathogenic effects of these mutations.  In cases when the 
mutation effects, such as the induction of a gating pore, are not targeted by traditional 
AEDs, patients will likely require novel AEDs that target the biophysical defect in order 
to effectively suppress their seizures.   Moreover, AEDs that preferentially inhibit 
aberrant Nav currents resulting from epilepsy mutation will likely prove to be efficacious 
at doses that minimally disturb the normal activity of the channels, allowing patients to 
be seizure-free without significant impairment of normal brain activity.  My results 
suggest that CBD and GS967 preferentially inhibit resurgent and persistent Nav currents, 
respectively, over transient Nav currents, and, thus, that these compounds may be more 
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potent and efficacious than traditional AEDs in the treatment of refractory SCN2A-
associated epilepsy. 
 Overall, this thesis addressed gaps in our understanding of the potentially 
pathogenic biophysical effects of epileptogenic SCN2A mutations and in our 
understanding of the mechanisms of action of two novel antiepileptic compounds.  The 
results may guide future studies of epileptogenic Nav channel mutations and screens of 
antiepileptic compounds to include resurgent and gating pore currents as potential 
biophysical effects of the mutations and as potential therapeutic targets.  Tailoring the 
treatment to block the particular pathogenic effects of the patient’s epilepsy mutation 
will allow for more targeted and effective suppression of both manageable and 
refractory seizures. 
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